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Abstract
Cancer is one of the leading causes of death worldwide. Among various chemothera-
peutic drugs currently used in cancer treatment, cisplatin is one of the most impor-
tant and successful drugs. It is the best hope for patients with testicular, ovarian and
many other solid tumors. Cisplatin kills cancer cells by covalently binding to their
DNA and causing DNA damages (cisplatin-DNA adducts). Albeit very efficient,
cisplatin’s clinical utility is limited due to its toxic side effects and resistance.
The mechanisms behind drug resistance are far from being completely understood.
Experimental studies so far have suggested that binding of cisplatin to many cellular
proteins is a key mechanism of drug resistance. In particular, the copper influx
protein Ctr1 has been shown to be responsible for the decrease of cellular uptake
of cisplatin, commonly found in resistant cells. Furthermore, even if cisplatin can
successfully reach and bind to the DNA, cancer cells may be able to repair the
cisplatin-DNA adducts by employing a number of proteins involved in the so-called
Nucleotide Excision Repair (NER) pathway.
This thesis has contributed to investigating processes, which are relevant to cisplatin
resistance mechanism, using computational physics tools.
(i) First, we have studied binding of cisplatin and transplatin (a pharmacologi-
cally inactive trans isomer of cisplatin) to a model peptide (called Mets7) that
mimics one of the methionine(Met)-rich motifs of Ctr1. We have used a set
of computational tools including QM/MM simulations, force matching tech-
nique, replica exchange MD simulations and computational spectroscopy to
predict the structures of the adducts formed due to the binding of cisplatin
and transplatin to Mets7. Comparison between calculated and experimental
spectroscopic data such as NMR, EXAFS and CD allows us to validate our
predicted structures and to propose the most relevant species in water solu-
tion. The structural models arising from our calculations may serve as the
molecular basis for further attempts to understand cisplatin uptake mediated
by Ctr1.
(ii) Then, we have performed preliminary calculations on the interaction between
cisplatin-DNA adduct and the High Mobility Group Box 1 (HMGB1) pro-
tein. HMGB1 (a DNA-binding protein) has been shown to be able to block
the NER repair pathway by binding to the cisplatin-DNA adducts and shield-
ing them from being repaired by NER proteins. Although experimental studies
have shown the structural determinants of the cisplatin-DNA-HMGB1 complex
and also provided the binding affinity, the mechanism of molecular recognition
between cisplatin-DNA adduct and HMGB1 is still unknown. We aim at in-
vestigating structural and energetic insights of the binding of HMGB1 to the
cisplatin-DNA adduct by applying free energy calculations based on metady-
namics method. This thesis presents necessary calculations towards this goal.
Kurzfassung
Krebs ist eine der ha¨ufigsten Todesursachen weltweit. Unter den verschiedenen
Chemotherapeutika, welche derzeit in der Krebsbehandlung eingesetzt werden, ist
Cisplatin einer der wichtigsten und erfolgreichsten Wirkstoffe. Er ist die beste ther-
apeutische Maßnahme fu¨r Patienten mit Hoden-, Eierstock- und vielen anderen soli-
den Tumoren. Cisplatin to¨tet Krebszellen durch kovalente Bindung an ihre DNA,
wodurch Scha¨den an der DNA hervorgerufen werden (Cisplatin-DNA Addukte).
Trotz sehr großer Effizienz ist die klinische Verwendbarkeit von Cisplatin aufgrund
der toxischen Nebenwirkungen und Resistenzen beschra¨nkt.
Die Mechanismen der Wirkstoff-Resistenzen sind bei weitem noch nicht vollsta¨ndig
verstanden. Experimentelle Studien haben bislang vorgeschlagen, dass die Bindung
von Cisplatin an viele zellula¨re Proteine ein wichtiger Resistenz-Mechanismus ist.
Insbesondere wurde gezeigt, dass das Kupfer-Transportprotein Ctr1 fu¨r die Ver-
ringerung der zellula¨ren Aufnahme von Cisplatin, was in resistenten Zellen ha¨ufig
gefunden wird, verantwortlich ist. Selbst wenn Cisplatin die DNA erfolgreich erre-
ichen und anbinden kann, ko¨nnen Krebszellen in der Lage sein, die Cisplatin-DNA-
Addukte unter Verwendung einer Reihe von Proteinen, welche in den sogenannten
Nukleotidexzisionsreparatur-(NER)-Pfad eingebunden sind, zu reparieren.
Diese Doktorarbeit hat zur Untersuchung von Prozessen, welche fu¨r Cisplatin-Resistenz
Mechanismen relevant sind, unter Verwendung von Computational Physics Metho-
den beigetragen.
(i) Zuna¨chst haben wir die Bindung von Cisplatin und Transplatin (ein pharmakol-
ogisch inaktives trans-Isomer von Cisplatin) an ein Modell-Peptid (Mets7) un-
tersucht, welches eines der Methionin(Met)-reichen Motive von Ctr1 nachahmt.
Wir haben eine Reihe von computergestu¨tzten Methoden einschließlich QM/MM-
Simulationen, Force-Matching-Verfahren, Replica-Exchange MD Simulationen
und computergestu¨tzte Spektroskopie verwendet, um Strukturen der Addukte,
welche durch die Bindung von Cisplatin und Transplatin an Mets7 gebildet wer-
den, vorherzusagen. Ein Vergleich zwischen berechneten und experimentellen
spektroskopischen Daten wie NMR, EXAFS und CD ermo¨glicht es uns, unsere
vorhergesagten Strukturen zu validieren und die wichtigsten Spezies in wa¨ss-
riger Lo¨sung vorzuschlagen. Die aus unseren Berechnungen hervorgegangenen
strukturellen Modelle ko¨nnen als molekulare Grundlage fu¨r weitere Versuche,
die durch Ctr1 vermittelte Aufnahme von Cisplatin zu verstehen, dienen.
(ii) Dann haben wir vorla¨ufige Berechnungen zur Wechselwirkung zwischen einem
Cisplatin-DNA-Addukt und dem High-Mobility-Group-Box-1-(HMGB1)-Protein
durchgefu¨hrt. Es wurde gezeigt, dass das HMGB1 (ein DNA-bindendes Pro-
tein) in der Lage ist, den NER Reparaturweg durch Bindung an die Cisplatin-
DNA-Addukte und durch deren Abschirmung, welche die Reparatur mit NER
Proteinen verhindert, zu blockieren. Obwohl experimentelle Studien die struk-
turellen Bestimmungsparameter der Cisplatin-DNA-HMGB1-Komplexe aufgezeigt
und auch Bindungsaffinita¨ten geliefert haben, ist der Mechanismus der moleku-
laren Erkennung zwischen dem Cisplatin-DNA-Addukt und HMGB1 noch un-
bekannt. Wir zielen darauf ab, strukturelle und energetische Erkenntnisse hin-
sichtlich der Bindung von HMGB1 an das Cisplatin-DNA-Addukt zu gewinnen,
indem auf der Metadynamik Methode beruhende freie Energie Berechnungen
durchgefu¨hrt werden. Diese Arbeit pra¨sentiert die fu¨r dieses Ziel notwendigen
Berechnungen.
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1
Introduction
The discovery of the pharmacological properties of cisplatin (Fig. 1.1a) has been an
utmost important event in cancer research [1, 2, 3, 4, 5, 6]. The approval of cisplatin
by U.S. Food and Drug Administration back in 1978 revolutionized anticancer ther-
apy [7, 8]. Today, cisplatin is one of the most important anticancer drugs [1, 2]. It
is widely used in clinics to treat various types of cancers, such as testicular, ovarian,
cervical, head and neck, esophageal, and small-cell lung cancers [1, 2, 4, 8]. Cisplatin
is especially effective in the treatment of testicular cancer with the overall cure rate
exceeding 90% [4, 7]. In contrast with cisplatin, its geometrical isomer, transplatin
(Fig. 1.1b), is inactive against cancers.
Figure 1.1 Chemical structures of a) cisplatin (cis-diamminedichloroplatinum(II))
and b) transplatin (trans-diamminedichloridoplatinum(II)).
DNA is believed to be the primary target of cisplatin [1, 2, 3, 4, 9]. Cisplatin kills
cancer cells by covalently binding to their DNA at adjacent guanine (G) bases and
causing the formation of intra-strand cross-links in the DNA (called cisplatin-DNA
adducts) [9, 12, 20]. The cisplatin-DNA adducts in turn inhibit DNA replication
[21, 22] and transcription [24, 25]. Since these are extremely important cellular
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processes, their inhibition causes tumor cells to undergo suicide via the so-called
apoptosis process (programmed cell death) [2, 28].
To reach its target, cisplatin takes a long journey, from the blood stream to the
tumor cell’s nucleus, where the DNA is located. On that route, cisplatin binds to a
variety of proteins (Fig. 1.2). This causes several major drawbacks. First, protein
binding may lead to harmful side effects [9, 29, 143]. Hence, cisplatin is toxic.
Second, binding to proteins is exploited by the tumor cells for the development of
drug resistance [2, 4, 28, 30, 85, 86]. The latter is correlated to a decrease in the rate
of drug influx and to an increase in the rate of drug eﬄux/deactivation, with respect
to non-resistant cells [2, 30, 82]. It follows that only a small fraction of the drug
given to patients (about 1%) reaches DNA [30, 87]. Furthermore, drug-resistant cells
are able to repair cisplatin-induced DNA damages [2, 4, 28]. They use a number
of proteins involved in the so-called Nucleotide Excision Repair (NER) pathway
to remove platinated nucleotides from the DNA, allowing cancer cells to survive
[2, 28, 86, 98]. Second generation platinum-based drugs currently used in clinics such
as oxaliplatin and carboplatin essentially suffers from the same problems [2, 4, 14, 24].
Understanding and eventually counteracting drug toxicity and resistance require a
detailed knowledge of the molecular events associated with cisplatin’s cellular uptake
and platinated DNA repair mechanisms [28, 29, 86, 110]. What we have known
so far originates exclusively from experimental studies and it is summarized here
[29, 30, 31]:
(i) Cisplatin enters the cell by passive diffusion [30, 31] and by trans-membrane
proteins, such as the copper transporter 1 (Ctr1) [29, 30, 110] (Fig. 1.2).
(ii) Once inside the cell, cisplatin can follow rather different fates (Fig. 1.2):
Deactivation: Cisplatin can be deactivated by binding to many proteins, in-
cluding the thiol-rich metallothioneins (MTs), glutathione (GSH) [32] and the
copper chaperone Atox1 [33, 34].
Increase of eﬄux: The copper eﬄux proteins ATP7A and ATP7B in the se-
cretory vesicle have been found to bind cisplatin and enhance its eﬄux [33].
Binding to DNA: Only a small fraction of cisplatin, which evades the inactiva-
tion and eﬄux processes above, enters the nucleus by an as-yet undetermined
mechanism and interacts with DNA [30]. There, NER repair mechanism may
take place. Some proteins, such as the High Mobility Group Box 1 (HMGB1)
protein [1, 24, 76, 78], have been found to inhibit the NER repair mechanism
by binding specifically to the cisplatin-DNA adduct and shielding it from being
repaired by NER proteins [72, 73, 74].
Structural information on the cisplatin-protein adducts involved in all of these pro-
cesses is essential to improve our understanding of drug resistance mechanism and
to design new drugs with reduced resistance and increased ability to bind to DNA.
Unfortunately, such information is mostly lacking, with a notable exception of the
complex between HMGB1 and platinated DNA [76].
Computational approaches are widely used to investigate cisplatin and other plat-
inum drugs and their interactions with biomolecules [45]–[62], [155]–[165]. However,
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Figure 1.2 A simplified scheme of the mechanisms affecting cellular uptake, dis-
tribution and eﬄux of cisplatin (adapted from [30]).
almost all of the computational studies so far have focused mainly on structural
properties of adducts of cisplatin and other platinum drugs with DNA [45]–[62].
The key issues of toxicity and resistance of cisplatin have been much less investi-
gated computationally. This thesis is meant to provide one of the first contributions
in this field. It focuses on two aspects:
(i) Binding of cisplatin and its isomer transplatin to a copper transport protein
called Ctr1. Ctr1 is a trans-membrane protein, located on the cell’s surface
[111, 112, 113, 114, 115] (Fig. 1.2). It has been found to transport cisplatin
across the cell’s membrane [29, 30, 110] although the exact transport mecha-
nism is still unknown. Here, using computational approaches, we have provided
the molecular structures of complexes of cisplatin and transplatin with a pep-
tide (called Mets7) that mimics the extracellular binding domain of Ctr1 [63].
Validation of our numerical results by biophysical experiments is fundamental.
Therefore, the computational protocols presented in this thesis have been cho-
sen to make comparison with available experimental data as direct as possible.
Starting from molecular simulations we have computed NMR, EXAFS and
CD spectra, which have been systematically compared with the correspond-
ing experimental data. This approach represents a significant improvement
with respect to the computational studies published so far, dealing essentially
with the comparison between computed and experimental structures [45]–[62],
[155]–[165]. Indeed, the computation of spectroscopic data allows a more direct,
hence, reliable comparison with experiment. The molecular structures arising
from our simulations can serve as the molecular basis for further attempts to
elucidate the mechanism of cellular uptake of cisplatin.
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(ii) Investigation of the mechanism of molecular recognition between cisplatin-DNA
adduct and HMGB1 protein. The free energy profile as a function of reaction
coordinates describing the association process of HMGB1 protein and cisplatin-
DNA adduct is a key physical quantity to elucidate the molecular mechanism of
the binding process. The free energy difference can be quantitatively correlated
with the experimental binding affinity [283]. This thesis presents preliminary
calculations, which will serve as a basis to perform free energy calculations
using metadynamics method [284, 285].
2
Biophysical background
2.1 Introduction
The antitumor effect of cisplatin was discovered by chance by Barnett Rosenberg at
Michigan State University in 1965 [5, 6, 8]. The drug was approved for clinical use by
the U.S. Food and Drug Administration (ADF) in 1978 [8]. Cisplatin is an inorganic
compound, in which a Pt(II) ion is coordinated by two ammine and two chlorido
ligands in cis square planar geometry (Fig. 1.1a). Its geometrical isomer, transplatin
has the same chemical composition, but the ligands are in trans arrangement (Fig.
1.1b). While cisplatin is active against many tumors, transplatin is not [10].
Nowadays, cisplatin is routinely used in clinics either as a single agent or in combi-
nation therapy to treat various types of cancers such as testicular, ovarian, small-cell
lung, head and neck, cervical, and colorectal cancers [1, 2, 11]. Cisplatin is particu-
larly effective against testicular cancer, for which the overall cure rate exceeds 90%,
or nearly 100% for early stage disease [7].
However, cisplatin suffers from two major shortcomings: toxic side effects and resis-
tance [1, 4, 28, 13]. Treatment with cisplatin indeed causes severe side effects such as
nephrotoxicity, nausea and vomiting, bone marrow damage and neurotoxicity [13].
Moreover, many tumor cells displays intrinsic or acquired resistance to cisplatin,
which further limits its clinical utility [2, 4]. These problems of cisplatin have gener-
ated a large interest in developing new platinum-based drugs with a better clinical
profile [2, 3, 14]. This has led to the discovery and approval of second generation
of platinum drugs, including carboplatin and oxaliplatin. However, these drugs also
suffer from resistance [1, 2, 14]. The efforts to overcome cisplatin resistance have been
proven very challenging and require a detailed knowledge of how cisplatin induces
its antitumor effect and, more importantly, how tumors are or become resistant.
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2.2 Mechanism of action
DNA binding is believed to be a key cellular event that triggers the anticancer ac-
tivity of cisplatin [1, 2, 4, 9]. Studies over many years have provided convincing
evidences in favor of this hypothesis [1]. Bacteria treated with cisplatin show phe-
notypes that are characteristic of those evoked by DNA-damaging agents [15]. In
addition, DNA-repair-deficient cells are indeed more sensitive to cisplatin [16, 17].
There is a significant correlation between cisplatin-DNA adduct levels and sensitivity
of cisplatin-treated cells [18, 19].
Cisplatin binds to DNA, preferentially at the N7 position of guanine bases [9, 20, 23],
inhibiting replication [9, 21, 22] and transcription of the DNA [24, 25, 26, 27]. The
inhibition of these critical DNA-related processes triggers subsequent intracellular
events leading to apoptotic cell death [28]. However, before binding to the DNA,
cisplatin has to survive a long journey from the blood stream to the tumor cell’s
nucleus where DNA is located. The current knowledge on the steps leading cisplatin
from intravenous injection to nuclear DNA binding can be summarized as follows
(Fig. 1.2) [29, 30, 31].
(i) Cisplatin diffuses in the blood stream and in the extracellular fluids, where
the chloride (Cl−) concentration is relatively high (∼100mM) [29, 30]. The
high concentration of chloride prevents cisplatin from undergoing aquation re-
actions, which transform cisplatin into activated monoaquated or diaquated
species (cis-[Pt(NH3)2H2OCl]
+ and cis-[Pt(NH3)2(H2O)2]
2+). Therefore, cis-
platin can reach the cancer cells’ surface in the intact neutral form [31].
(ii) Cisplatin enters cells both by passive diffusion across the cell membrane and
by active transport using the high-affinity copper transporter 1 Ctr1 and the
organic cation transporters OCT1–3 [30]. Pinocytosis, characterized by the
formation of an endocytic vesicle incorporating a portion of external solution
containing all chemicals there present (including cisplatin), is another possibil-
ity of drug uptake [132] (Fig. 1.2).
(iii) Once inside the cell, the lower concentration of chloride in the cytoplasm (4–
50mM) facilitates the aquation process of cisplatin to form cis-[Pt(NH3)2H2OCl]
+
and cis-[Pt(NH3)2(H2O)2]
2+ [30, 31]. The aquated forms are more reactive to-
wards cellular targets. Although DNA is the primary target of cisplatin, many
other nucleophilic components present in the cytosol can bind cisplatin. These
include thiol-rich metallothioneins (MTs), glutathione (GSH) [32] and the cop-
per chaperone Atox1 [33, 34]. All of these proteins sequester cisplatin, and
eventually deactivate it. Cisplatin can also be exported out of the cell by the
copper pumps ATP7A and ATP7B in the secretory vesicles. These proteins
can bind and enhance cisplatin eﬄux [33]. Finally, only a small fraction of
cisplatin, which evades the inactivation and eﬄux processes above, enters the
nucleus by an as-yet undetermined mechanism and bind to DNA, triggering
apoptotic cell death if the DNA lesion is not repaired [30, 31].
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2.2.1 Cisplatin-DNA adducts
Cisplatin forms a spectrum of intra- and inter-strand DNA cross-links, which have
been identified both in vitro and in vivo (Fig. 2.1) [1, 24, 35, 36, 37, 38]. The major
adduct, comprising ∼65% of the total products, is a cis-1,2-[Pt(NH3)2]2+-d(GpG)
intra-strand cross-link (Fig. 2.1a) [1]. Other minor products include 1,2-d(ApG)
(∼25%) and 1,3-d(GpNpG) (Fig. 2.1b) (5–10%) intra-strand adducts, as well as
a smaller number of inter-strand cross-links (Fig. 2.1c) and monodentate adducts
[1]. Transplatin, a clinically inactive isomer of cisplatin (Fig. 1.1b) is unable to
form 1,2-intra-strand cross-links, due to stereo-chemical constraints [39, 40]. This
implies that intra-strand adducts are more likely to be responsible for the anticancer
activity of cisplatin [1]. There is no correlation between the frequency of inter-strand
cross-links formation and cytotoxicity of cisplatin, which provides further evidence
that intra-strand cross-links are essential to tumor cell death [1, 39, 40].
Figure 2.1 Major cisplatin-DNA adducts: (a) 1,2-[Pt(NH3)2]
2+-d(GpG) intra-
strand cross-link; (b) 1,3-[Pt(NH3)2]
2+-d(GpTpG) intra-strand cross-
link; (c) inter-strand cross-link (adapted from [24]). DNA’s backbone
is shown in ribbon; their nucleobases in bond representation; the plat-
inum atom is represented as a sphere.
The X-ray structure of a platinated DNA dodecamer duplex containing the major
cis-1,2-[Pt(NH3)2]
2+-d(GpG) intra-strand cross-link revealed that DNA platination
induces a global bend in the DNA duplex by 35◦–40◦ and unwinds the double helix
by ∼25◦ [1, 24, 41, 42] (Fig. 2.2a). The major groove is compacted and the minor
groove widened and flattened. The DNA takes on A-form properties to the 5’ and
a B-form structure on the 3’ side of the 1,2-d(GpG) adduct. The roll angle be-
tween platinated guanine bases is ∼26◦ [41]. NMR spectroscopic studies [1, 43, 44]
revealed some differences between the solid state and solution structures. The so-
lution structures (Fig. 2.2b) shows a bend angle of 60◦–70◦ and a large roll angle
of ∼49◦ at the 1,2-[Pt(NH3)2]2+-d(GpG) intra-strand cross-link. In addition, the
NMR structures contain exclusively B-form DNA. The 1,3-[Pt(NH3)2]
2+-d(GpTpG)
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intra-strand cross-link on the duplex DNA (Fig. 2.1(b)) has also been solved by
NMR spectroscopy [64, 65]. In this structure, the duplex is bent by ∼30◦ and the
double helix displays local unwinding and widening of the minor groove, similarly to
features of the 1,2-[Pt(NH3)2]
2+-d(GpG) intra-strand cross-link. However, the 1,3-
[Pt(NH3)2]
2+-d(GpTpG) adduct differs in that base pairing of the 5’ G*-C, where
the “*” denotes the platinated site, is disrupted and the internal thymidine of the
adduct is extruded from the minor groove [24].
(a) (b) 
Figure 2.2 Structures of cisplatin-DNA adduct: (a) from X-ray [41] and (b) from
NMR [44]. Atoms in DNA are represented by lines while the cisplatin
moiety is shown in ball-stick model (platinum in gray, nitrogen in blue).
2.2.2 Recognition of cisplatin-DNA adducts: HMGB1 protein
Many proteins have been identified to bind to cisplatin-DNA adducts [1, 9, 24]. These
include High Mobility Group Box (HMGB) proteins, repair proteins, transcription
factor proteins and others [1, 3, 24]. Among these proteins, the High Mobility
Group Box 1 (HMGB1) protein has been extensively studied, and for which most
information is available.
HMGB1 protein is one of the early proteins discovered to bind cisplatin-DNA adducts
[66, 67]. HMGB1 is an abundant protein (∼106 copies per cell) [68]. It has been
suggested that HMGB1 play an important role in regulation of many cellular pro-
cesses involving DNA, such as, chromatin remodeling, recombination, replication,
and transcription [68, 69]. HMGB1 expression levels have been shown to correlate
with cisplatin sensitivity. In vitro repair essays revealed that HMGB1 can inhibit
Nucleotide Excision Repair (NER) of cisplatin-DNA adducts (see Sec. 2.3), presum-
ably by binding to and shielding the damaged site from recognition by the repair
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proteins [70, 71, 72, 73, 74]. An increased level of HMGB1 following hormone treat-
ment sensitizes breast cancer cells to cisplatin by 2-fold (the number of cancer cells
killed by cisplatin increases twice when treated with the same amount of drug) [74].
Moreover, additional expression of HMGB2, a protein over 85% identical to HMGB1,
in human lung cancer cells enhanced cisplatin sensitivity more than 3-fold [75].
The structure of a complex between 16mer duplex DNA containing a 1,2-[Pt(NH3)2]
2+-
d(GpG) intra-strand cross-link and the domain A of HMGB1 was solved by X-ray
crystallography (Fig 2.3) [76]. HMGB1 domain A contains three alpha helices form-
ing an L-shape structure that facilitates DNA binding [77]. The concave surfaces of
HMGB1 domain A form hydrogen bonds as well as hydrophobic and water-bridging
contacts with the minor groove of the platinated DNA. Phe37 intercalates into the
hydrophobic cleft formed by the two platinated guanines bases G8 and G9 (Fig.
2.3) [76]. The binding affinity between HMGB1 and cisplatin-DNA adduct was also
measured (Kd = 0.7± 0.1 nM ) (see Sec. 5.1 for the definition of Kd) [78].
Pt 
PHE37 
G9 
G8 
HMGB1 
DNA 
Figure 2.3 X-ray structure of the complex between HMGB1 domain
A and cis-[Pt(II)(NH3)2]-d-(CCUCTCTG*G*ACCTTCC)-
d(GGAGAGACCTGGAAGG) (PDB code 1CKT) [76]. The DNA’s
backbone is shown in blue ribbon; nucleobases in blue bonds; cisplatin
moiety in van der Waals balls. The HMGB1’s backbone is shown in
red ribbon; its Phe37 amino acid, which inserts between two platinated
G8 and G9 bases, is shown in green ball-stick representation.
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2.3 Mechanisms of Resistance
The development of resistance is a common drawback of chemotherapy, and cisplatin
is no exception [4, 79]. It is a major cause of treatment failure [4]. Resistance
implies that tumor cells fail to undergo apoptosis (programmed cell death) at a
clinically relevant drug concentration [28]. Some tumors, such as colorectal cancer
and non-small-cell lung cancer are intrinsically resistant to cisplatin chemotherapy
[80]. Other tumor types, such as head and neck cancer, testicular cancer, ovarian
cancer and small-cell lung cancer are predominantly sensitive to cisplatin treatment.
However, most of these sensitive tumors develop acquired resistance after the initial
treatment [4]. The mechanisms by which tumor cells develop resistance to cisplatin
are multifactorial, and not completely understood [3, 28, 30, 81, 85]. The generally
accepted mechanisms [2, 28, 30, 85, 86] by which cancer cells acquire resistance to
cisplatin are: (i) decreased accumulation of cisplatin, (ii) increased deactivation of
cisplatin by thiol-containing molecules and (iii) increased repair of DNA adducts.
Figure 2.4 Correlation between the fold-resistance (which is defined as the fold
increase in the number of survival cells when treated with the same
amount of drug) and the percent decrease in cisplatin accumulation
with respect to sensitive cells (adapted from [30]).
(i) Decreased accumulation of cisplatin: This is the most common and dis-
tinctive feature of resistant cells [28, 30]. It has been observed repeatedly in
different types of tumor cells that cisplatin accumulation in resistant cells is
reduced significantly in comparison to that in sensitive cells [2, 30, 82]. Re-
sistant cells have apparently altered the cellular transport machinery so as to
reduce the amount of cisplatin to reach the target DNA. Over many years,
several studies have been devoted to investigate the ability of cisplatin and
other platinum drugs to accumulate in cancer cells. It has been consistently
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demonstrated that accumulation of the drug is a determinant of cellular sensi-
tivity to cisplatin [83, 84]. In most of human- and rodent- cell lines, which are
resistant to cisplatin, its accumulation is reduced relative to the non-resistant
cells [30, 87]. A strong correlation between cisplatin accumulation and relative
cisplatin resistance were observed for a series of increasing resistant cell lines
derived from the BEL7404 human hepatoma cell line (Fig. 2.4) [88]. More-
over, Koga et al. examined seven primary bladder cancer cell lines derived
from untreated cancer of urinary bladder and found a positive correlation be-
tween cisplatin accumulation and sensitivity among the intrinsically resistant
cell lines [30, 89]. Diminished accumulation has been observed not only for cis-
platin but also for carboplatin [90] and oxaliplatin [91]. Reduced intracellular
accumulation of cisplatin is due to either decreased uptake or increased eﬄux
or both. It is, therefore, important to understand the molecular mechanisms
of cellular uptake and eﬄux of cisplatin.
(ii) Increased deactivation of cisplatin by thiol-containing molecules: Thiol
(SH)-containing molecules such as intracellular tripeptide glutathione (GSH)
or metallothioneins (a class of low-molecular weight proteins) are able to bind
and deactivate cisplatin [4, 28, 92]. GSH reacts with cisplatin and other elec-
trophilic compounds to form deactivated conjugates that are readily excreted
by a GS-conjugated export pump [93]. Early studies using eight human ovar-
ian carcinoma cell lines showed a significant correlation between sensitivity to
cisplatin, and levels of GSH [28, 94]. A study of two ovarian cancer cell lines
that were derived from the same patient before and after the onset of drug
resistance showed 2.9-fold higher levels of GSH in the cells derived from the
drug-resistant tumor [95]. Over-expression of metallothioneins, that are in-
volved in heavy-metal binding and detoxification, in either mouse cells [96] or
in human ovarian cancer cells [97] led to 4-fold or 7-fold increase in cisplatin
resistance, respectively.
(iii) Increased repair of DNA adducts: An important biochemical mechanism
of resistance is the repair of cisplatin-DNA adducts [2, 4, 28, 86, 98]. Many
cisplatin-resistant cell lines that are derived from various tumor types have
been shown to have increased DNA-repair capacity in comparison to sensitive
counterparts [99]. Nucleotide Excision Repair (NER) is a major mechanism of
cisplatin-damaged DNA repair. Increased NER in cisplatin-resistant cell lines
has been shown to occur both for intra-strand as well as inter-strand cisplatin-
DNA adducts [100, 101]. NER is an ATP-dependent multi-protein complex
that recognizes the kink induced on the DNA by 1,2-intrastrand cross-link and
subsequently excises the segment containing the kink. The gap is then filled
by DNA polymerase [102]. Increased removal of DNA adducts by NER in
resistant cell lines relative to sensitive parent cell lines has been consistently
observed in several models [9, 103]. Conversely, defective NER has been found
in cell lines with hypersensitivity to cisplatin [104].
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2.4 Copper transport proteins and their binding to
cisplatin
Reduced cellular accumulation of cisplatin is a major mechanism of drug resistance
[2, 30, 82]. Therefore, it is vitally important to understand how the cellular trans-
port machinery of cisplatin works. For a long time, cisplatin was believed to enter
cells only by passive diffusion [105, 106, 107, 108, 109]. Although passive diffusion
mechanism has been not fully ruled out, recently there has been a growing body
of evidence indicating that cisplatin as well as other platinum drugs enter cells, are
distributed to various sub-cellular compartments, and exported from the cells via
transport proteins that evolved to manage copper homeostasis [29, 30, 110, 131, 132].
In particular, the high-affinity copper transporter 1 (Ctr1) has been shown to be
involved in the uptake of cisplatin and other platinum drugs across the cells’ mem-
brane, whereas the ATPase copper pumps ATP7A and ATP7B are responsible for
sequestration and eﬄux of cisplatin [30].
2.4.1 Ctr1
Ctr1 is an evolutionarily conserved copper uptake protein present in plants, yeast
and mammals. It is the main copper importer in mammalian cells [111, 112, 113, 114,
115]. Ctr1 in human is expressed in all tissues. It plays a key role in homeostatic reg-
ulation of cellular copper levels. Recently, Ctr1 has been demonstrated to regulate
the cytotoxicity of cisplatin by affecting drug uptake [116, 117, 118, 119, 120, 121].
The absence of Ctr1 expression causes yeast and mammalian cells resistant to cis-
platin, carboplatin and oxaliplatin [116, 117, 118, 119, 122]. On the other hand,
over-expression of Ctr1 was shown to sensitize cells to the toxic effects of cisplatin
[118, 123]. These changes in sensitivity are accompanied by proportionate changes
in the uptake of cisplatin and other platinum agents [110]. In vivo studies in rats
showed that cisplatin cause atrophy in those cells in dorsal root ganglia that ex-
pressed high levels of Ctr1 but not those with low-level expression [124]. It was
recently demonstrated that knockout of Ctr1 completely eliminates responsiveness
of tumors to cisplatin in vivo in a murine model [122].
Molecular aspects:
Ctr1 is a membrane protein having three trans-membrane domains. A homotrimer
of Ctr1 forms a pore in the lipid bilayer (Fig. 2.5). The extracellular domain of
Ctr1 caries several methionine-rich motifs, which have been identified as a putative
cisplatin binding site [142].
To provide insights on interactions of Ctr1 with cisplatin, transplatin and other
platinum complexes, Arnesano et al. chose one of the Met-rich motifs of yeast Ctr1
(called Mets7) with slight modification [144] to make it more water-soluble and
performed the reaction with cisplatin, transplatin and other platinum complexes
[142, 143]. The investigation was performed using mainly electrospray ionization
mass spectroscopy (ESI-MS), NMR and circular dichroism (CD).
CD measurements showed that Mets7 features a β-turn conformation after reacting
with cisplatin, whilst it is a random coil in the Apo form [142]. Transplatin was
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Figure 2.5 Cartoon representing the copper influx transporter Ctr1 (adapted from
[145]). Left: Ctr1 is a symmetrical homotrimeric trans-membrane pro-
tein. Nine trans-membrane helices form a pore in the lipid bilayer.
Each subunit is represented by a different color. Right: One of the
three subunits is removed to reveal the interior of the pore.
shown to modify just slightly the random coil of Mets7. ESI-MS data showed that
cisplatin progressively loses all ammine and chlorido ligands and ultimately coordi-
nates only to Mets7. This contrasts with transplatin, which keeps the two ammine
ligands [142, 143]. Consistently, 1H/13C heteronuclear single-quantum coherence
(HSQC) spectra (Fig. 2.6) reveals a large downfield shift of the 1H and 13C nuclei
of -CH3 and γ-CH2 of methionines and confirms coordination of Pt to the S atoms.
Other groups also reported a similar binding mode of cisplatin to partial or full-
length N-terminal domain of human Ctr1 [146, 147]. Hence, Mets7 is a good mimic
of the whole N-terminal domain of Ctr1 in terms of reactivity against cisplatin. The
full structural determinants of cisplatin- and transplatin-Mets7 adducts are so far
lacking.
2.4.2 ATP7A, ATP7B and Atox1
ATP7A and ATP7B are functionally conserved P-type ATPases involved in the se-
questration and extrusion of excess Cu ions [30, 113, 125, 126, 112]. The two proteins
are homologous in structure, sharing 8 trans-membrane domains and ∼65% amino
acid sequence identity. However, they are expressed in different tissues: ATP7A
in intestinal epithelium and ATP7B in liver and kidney. Enhanced expression of
ATP7A and ATP7B has been linked to the degree of cisplatin resistance in tumor
cell lines and clinical samples [128]. Over-expression of ATP7B is associated with
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a reduced capacity in cells to accumulate cisplatin and show a high rate of eﬄux
[129]. A confocal microscopy study showed that an ECFP (enhanced cyan fluores-
cent protein)-tagged ATP7B (ATP7B-ECFP) colocalized with a fluorescence labeled
cisplatin (F-cisplatin) and that both of cisplatin and F-cisplatin caused trafficking of
the ATP7B-ECFP containing vesicles toward the cell’s surface [130]. This is consis-
tent with the role of ATP7B as an eﬄux transporter of cisplatin. On the other hand,
the function of ATP7A appears to be different from that of ATP7B [132]. Although
ATP7A over-expressing cells exhibit a significant degree of enhanced resistance to
cisplatin, higher levels of cisplatin accumulation were observed [133]. This indicates
that the function of ATP7A is likely to be in binding and sequestration of cisplatin
rather than exporting it [132, 133]. This was confirmed in many observations includ-
ing detection of significantly higher levels of cisplatin in the vesicular compartment
of the cells that over-express ATP7A [133]. Confocal microscopy demonstrated that
ATP7A and F-cisplatin colocalized in the vesicular structures in ovarian carcinoma
cells 2008 [134]. Exposure to cisplatin did not cause trafficking of the ATP7A con-
taining vesicles toward the cell surface [133].
Atox1 is a key metallochaperone that receives copper from the importer Ctr1 and
delivers it to the copper exporters ATP7A and ATP7B in the secretory compartment
[135, 136, 137, 112]. It has 69 amino acids and is found in the cystosol and nucleus
[135]. Loss of Atox1 in the fibroblast cells of mice has been found to reduce the influx
of cisplatin and subsequent accumulation in vesicular compartment and DNA [138].
The exact role of Atox1 in cellular transport and distribution of cisplatin is still not
fully understood. However, it has been suggested that Atox1 regulates the influx
of cisplatin by controlling the cisplatin-induced down regulation of Ctr1 through
ubiquitination [110, 138]. Atox1 has been found to translocate to the nucleus in
response to copper exposure [139, 140] and it has also recently been reported to
bind cisplatin [141, 34]. This raises the question of whether it could be involved in
the delivery of cisplatin to DNA.
Molecular aspects:
Solution and in-cell NMR spectroscopy study [34] showed that cisplatin binds to the
CxxC metal binding motif of Atox1 (Fig. 2.7a). Initially, a cis-[Pt(NH3)2]-Atox1
adducts is formed. At longer reaction time the protein dimmerization accompanied
by loss of the two ammine ligands is observed [34]. This interaction mode is different
from that observed previously by Boal et al. using X-ray crystallography technique
[141].
ATP7B features six soluble domains, each of which contains about 70 amino acids.
Their structures have been solved by NMR spectroscopy [148, 149]. Interestingly,
each domain has the similar fold as the Atox1 protein [150, 151]. All the domains
share the same CxxC metal binding motif (Fig. 2.7b). A likely model of the adducts
of cisplatin with ATP7B involves the binding of the cis-[Pt(NH3)2]
2+ moiety to the
CxxC motifs [152] as suggested by cysteine mutation experiments [153, 154].
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Figure 2.6 Overlay of 2D 1H,13C-edited HSQC spectra of Mets7 (red contours)
and of mixtures (1:1) of Mest7 with a) cisplatin and b) transplatin.
Spectral changes induced by cisplatin/transplatin are indicated with
arrows. Figures adapted from [142].
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a) b) 
Figure 2.7 The NMR structures of: (a) Atox1 [151] and (b): the soluble domain 4
of the ATP7B protein [148]. The backbone is represented with ribbon.
Different colors indicate different secondary-structure types: green is
loop, yellow is beta sheet, and purple is alpha helix. Two cysteine
amino acids are shown in bond representation.
3
Methods
3.1 Molecular dynamics
3.1.1 Statistical mechanical basis of molecular dynamics
Molecular dynamics simulations generate information at the microscopic level (atomic
positions, velocities...) and the connection of this very detailed information to macro-
scopic quantities (such as pressure, temperature, energy...) is provided by statistical
mechanics [255]. The set of atoms’ coordinates and momenta can be thought as
coordinates in a multidimensional space: the phase space. For a system of N atoms,
this space has 6N dimensions. Let us denote a particular point in the phase space
as Γ, and suppose that we can write the instantaneous value of some property A as
a function of Γ, A(Γ). The experimentally observable value of A, Aobs is given by
the ensemble average. Here, an ensemble is regarded as a collection of points Γ in
the phase space. The points are distributed according to a probability distribution
p(Γ). The ensemble average (or thermodynamic average) is written as
Aobs = 〈A〉ens =
∫
A(Γ)p(Γ)dΓ, (3.1)
where dΓ = d~R1 · · · d~RN · d~P1 · · · d~PN . The probability distribution depends on
macroscopic parameters (NV E, NV T , NPT ...), which defines the experimental
conditions. In the case where N , V and T are kept fixed (canonical ensemble),
the corresponding probability distribution is given by the Boltzmann distribution
function
pNV T =
exp [−H(Γ)/kBT ]
Z
, (3.2)
where
Z =
∫
dΓpNV T (Γ) =
∫
dΓ exp [−H(Γ)/kBT ] (3.3)
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is the canonical partition function, kB is the Boltzmann factor, H(Γ) is the classical
Hamiltonian of the system which is given by
H(Γ) = H
({
~RI
}
,
{
~PI
})
=
N∑
I=1
~P 2I
2MI
+ U
({
~RI
})
. (3.4)
~RI and ~PI are the coordinate and momentum of atom I, respectively. MI is the mass
of atom I. In order to calculate the ensemble average (Eq. (3.1)), it is necessary to
calculate the partition function (Eq. (3.3)), which is an extremely difficult task.
Molecular dynamics (MD) offers a strategy to calculate the ensemble average. In
this approach, the motion of a single point Γ through the phase space is followed as
a function of time. The time evolution of a single point Γ through the phase space is
obtained by integrating the equation of motion, starting from an initial point Γ(0).
The integration yields a trajectory that is a set of points Γ(t) describing the state of
the system at any successive time t. The “dynamical average” of A can be calculated
by averaging over those points that have been visited
〈A〉τ =
1
τ
τ∫
0
A [Γ(t)] dt. (3.5)
The two averages (3.1) and (3.5) are connected by the “ergodic hypothesis”. The
system is at equilibrium and if it is allowed to evolve infinitely long in time, then it
will pass through all its possible states. A system which obeys the conditions above
is said to be ergodic, and under these conditions the dynamical average is equal to
the ensemble average for an infinitely long trajectory
lim
τ→∞
〈A(Γ)〉τ = 〈A(Γ)〉Γ . (3.6)
The fact that all the “real” molecular systems are assumed to be ergodic is the
theoretical justification for using MD simulations as a means to calculate ensemble
averages of molecular systems [255]. In practice, the application of MD simulations
to calculate thermodynamic averages assumes that the system under investigation
is ergodic and that a finite simulation is a “good” approximation to the infinite
trajectory.
3.1.2 Derivation of molecular dynamics equation
The time-dependent behavior of molecular systems is best described by the time-
dependent Schro¨dinger equation. However, this equation is extremely difficult to
solve for large systems. Therefore, classical mechanical description is often used to
approximate the motion of atoms. In most of computational studies of biomolecules,
the Newtonian equations of motion of the classical mechanics are solved, rather
than the quantum mechanical equations. In this section, the classical equations of
molecular dynamics (Newton’s equations) will be derived from the time-dependent
Schro¨dinger equation [257, 258, 259].
The time-dependent Schro¨dinger equation is written as
i~
∂
∂t
Ψ
(
{~ri}, {~RI}; t
)
= HΨ
(
{~ri}, {~RI}; t
)
, (3.7)
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where H is the Hamiltonian of the system. For most of the biologically relevant
systems, the non-relativistic Hamiltonian is sufficient to get a reasonably accurate
description
H = −
∑
I
~2
2MI
∇2I −
∑
i
~2
2me
∇2i
+
1
4piε0
∑
i<j
e2
|~ri − ~rj| −
1
4piε0
∑
I,i
e2ZI∣∣∣~RI − ~ri∣∣∣ +
1
4piε0
∑
I<J
e2ZIZJ∣∣∣~RI − ~RJ ∣∣∣
= −
∑
I
~2
2MI
∇2I −
∑
i
~2
2me
∇2i +
1
4piε0
∑
i<j
e2
|~ri − ~rj| + Vn−e
(
{~ri}, {~RI}
)
= −
∑
I
~2
2MI
∇2I +He
(
{~ri}, {~RI}
)
. (3.8)
{~ri} and {~RI} denote the coordinates of the electrons and nuclei, respectively. MI
and ZI are the mass and atomic number of the I-th nucleus. me and −e are the elec-
tron’s mass and charge, respectively. ε0 is the vacuum permittivity. Ψ
(
{~ri}, {~RI}; t
)
is the total wavefunction.
In the one-determinant approximation ansatz [257, 258, 259], Ψ
(
{~ri}, {~RI}; t
)
is
separated into the electronic and nuclear contributions
Ψ
(
{~ri}, {~RI}; t
)
= φ ({~ri}; t)χ
(
{~RI}; t
)
exp
 i
~
t∫
t0
E˜e(t
′)dt′
 , (3.9)
where the nuclear and electronic wavefunctions are separately normalized to unity
at every instant of time, i.e.∫
|φ ({~ri}; t)|2 d~r = 〈φ, t |φ, t〉 = 1, ∀t ∈ R, (3.10)
∫ ∣∣∣χ({~RI}; t)∣∣∣2 d~R = 〈χ, t |χ, t〉 = 1, ∀t ∈ R, (3.11)
where d~r = d~r1 · · · d~rn and d~R = d~R1 · · · d~RN . The phase factor then can be written
as
E˜e =
∫
φ∗ ({~ri}; t)χ∗
(
{~Ri}; t
)
Heφ ({~ri}; t)χ
(
{~Ri}; t
)
d~rd~R. (3.12)
By inserting (3.9) and (3.12) into (3.7), multiplying from the left by φ∗χ∗, integrat-
ing over all nuclear and electronic coordinates and imposing energy conservation
condition
d
dt
∫
Ψ∗
(
{~ri}, {~Ri}; t
)
HΨ
(
{~ri}, {~Ri}; t
)
d~rd~R = 0, (3.13)
we obtain
i~
∂
∂t
φ = −
∑
i
~2
2me
∇2iφ+
{∫
χ∗
(
{~RI}; t
)
Vn−e
(
{~ri}, {~RI}
)
χ
(
{~RI}; t
)
d~R
}
φ,
(3.14)
20 3. Methods
i~
∂
∂t
χ = −
∑
I
~2
2MI
∇2Iχ+
{∫
φ∗ ({~ri}; t)He
(
{~ri}, {~RI}
)
φ ({~ri}; t) d~r
}
χ, (3.15)
which is a set of coupled time-dependent Schro¨dinger equations. The electrons move
in a time-dependent effective potential given by averaging over nuclear degrees of
freedom and vice versa.
Now we want to approximate the quantum mechanical equation for the nuclei (Eq.
(3.15)) as a classical mechanical equation. To this aim, we rewrite the nuclear
complex wavefunction χ
(
{~RI}; t
)
in a polar form
χ ({RI}; t) = A ({RI}; t) exp [iS ({RI}; t)/~] , (3.16)
where A is the amplitude and S is the phase. Substituting Eq. (3.16) into Eq. (3.15)
and separating the real and imaginary parts yields
∂S
∂t
+
∑
I
1
2MI
(∇IS)2 +
∫
φ∗Heφd~r = ~2
∑
I
1
2MI
∇2IA
A
, (3.17)
∂A
∂t
+
∑
I
1
MI
(∇IA)(∇IS) +
∑
I
1
2MI
A(∇2IS) = 0 (3.18)
Equation (3.18) for the amplitude A can be written as a continuity equation [257,
260, 261] by multiplying from the left by 2A:
∂A2
∂t
+
∑
I
1
MI
∇I(A2∇IS) = 0 (3.19)
Noting that the nuclear probability ρ = |χ|2 = A2 and the current density JI =
A2(∇IS)
MI
, Eq. (3.19) becomes
∂ρ
∂t
+
∑
I
∇IJI = 0. (3.20)
The continuity equation (3.20) ensures the conservation of particle probability χ2 of
the nuclei in the presence of a flux.
The expression of the phase S (Eq. (3.17)) contains one term that depends explicitly
on the Planck’s constant ~. This term vanishes in the classical limit ~→ 0, and Eq.
(3.17) becomes
∂S
∂t
+
∑
I
1
2MI
(∇IS)2 +
∫
φ∗Heφd~r = 0. (3.21)
If we set ∇IS to be the momentum of nucleus I
~PI = ∇IS (3.22)
then Eq. (3.21) becomes
∂S
∂t
+
∑
I
1
2MI
~P 2I +
∫
φ∗Heφd~r = 0. (3.23)
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This equation is isomorphic to the equation of motion in the Hamiltonian-Jacobi
formalism [257, 262] of classical mechanics
∂S
∂t
+H
(
{~RI}, {~PI}
)
= 0, (3.24)
in which
H
(
{~RI}, {~PI}
)
= T
(
{~PI}
)
+ V
(
{~RI}
)
=
∑
I
1
2MI
~P 2I +
∫
d~rφ∗Heφ, (3.25)
is the classical Hamilton function of the coordinates ~RI and the conjugate momenta
~PI . The corresponding Newtonian equation of motion is
d~PI
dt
= −~∇I
∫
d~rφ∗Heφ = −~∇IVe
(
{~RI}
)
, (3.26)
or
MI ~¨RI = −~∇I
∫
d~rφ∗Heφ. (3.27)
Therefore, in the classical limit (~→ 0), the nuclei move as classical particles in an
effective potential Ve, which is obtained by averaging over the electronic degrees of
freedom at a given instantaneous nuclear positions ~RI(t).
To calculate Ve we need to solve Eq. (3.14), which still contains the full quantum-
mechanical nuclear wavefunction. Therefore, we need to apply the classical limit
by replacing the nuclear density
∣∣∣χ{~RI}∣∣∣2 in Eq. (3.14) by a product of delta func-
tions
∏
I
δ
[
~RI − ~RI(t)
]
centered at the instantaneous nuclear positions RI(t). The
expectation value of the position operator becomes∫
d~Rχ∗
(
{~RI}; t
)
~RIχ
(
{~RI}; t
)
→ ~RI(t). (3.28)
This leads to a time-dependent wave equation for the electrons
i~
∂φ
∂t
= −
∑
i
~2
2me
∇2iφ+ Vn−e
(
{~ri}; {~RI(t)}
)
φ
= He
(
{~ri}; {~RI(t)}
)
φ
(
{~ri}; {~RI}; t
)
, (3.29)
which evolve self-consistently as the classical nuclei are propagated according to Eq.
(3.27).
3.1.3 Ab initio molecular dynamics
3.1.3.1 Ehrenfest MD
In this ab initio MD scheme, the Newton’s equations for the nuclei (Eq. (3.27))
are solved simultaneously with the time-dependent Schro¨dinger equation for the
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electrons (Eq. (3.29)). The time-dependent Schro¨dinger equation of the electrons is
solved “on-the-fly” as the nuclei are moving according to classical mechanics. This
is the so-called Ehrenfest MD scheme. The total electronic wavefunction φ in Eq.
(3.29) can be expanded in a basis of the electronic states ψl
φ
(
{~ri}; {~RI}; t
)
=
∞∑
l=0
cl(t)ψl
(
{~ri}; {~RI}
)
, (3.30)
where cl(t) are complex time-dependent coefficients, satisfying∑
l
|cl(t)|2 = 1. (3.31)
The basis functions ψl can be chosen as the instantaneous eigenstates of the time-
independent electronic Schro¨dinger equation
He
(
{~ri}; {~RI}
)
ψl
(
{~ri}; {~RI}
)
= El
(
{~RI}
)
ψl
(
{~ri}; {~RI}
)
, (3.32)
where ~RI are the instantaneous nuclear positions at time t which are determined
according to Eq. (3.27). With this choice of basis wavefunctions, the equations of
motion (3.27) and (3.29) become
MI ~¨RI(t) = −∇I
∑
k
|ck(t)|2Ek
= −
∑
k
|ck(t)|2∇IEk +
∑
k,l
c∗kcl (Ek − El) ~dklI , (3.33)
i~c˙k(t) = ck(t)Ek − i~
∑
l
cl(t)D
kl, (3.34)
where
Dkl =
∫
ψ∗k
∂
∂t
ψld~r =
∑
I
~˙RI
∫
ψ∗k∇Iψld~r =
∑
I
~RI ~d
kl
I . (3.35)
The restriction to one electronic state (in most cases the ground state ψ0) in Eq.
(3.30) leads the equations of motion (3.27) and (3.29) to
MI ~¨RI = −~∇I
∫
d~rψ∗0Heψ0, (3.36)
i~
∂ψ0
∂t
= Heψ0. (3.37)
The propagation of the wavefunction in Eq. (3.37) is unitary. This implies that
the wavefunction preserves its norm and the set of orbitals used to build up the
wavefunction will stay orthonormal [257].
3.1.3.2 Born-Oppenheimer MD
Another approach to ab initio MD is to solve the time-independent Schro¨dinger
equation for fixed instantaneous nuclear positions at each molecular dynamics step.
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In this case, the intrinsic dynamics of the electrons is lost. The time-dependence
of the electronic structure is imposed by the parametric dependence of He on the
classical dynamics of the nuclei. The equations of motion of this so-called “Born-
Oppenheimer” molecular dynamics are given by
MI ~¨RI(t) = −∇I min
ψ0
〈ψ0|He |ψ0〉 , (3.38)
Heψ0 = E0ψ0. (3.39)
A drawback of the Born-Oppenheimer scheme is that the electronic wavefunction ψ0
need to be obtained by minimizing 〈He〉 at every time step.
3.1.3.3 Car-Parrinello MD
In Ehrenfest MD method, the integration time step of the equations of motion is
dictated by the intrinsic dynamics of the electrons, which is much faster than nuclear
dynamics. Therefore, one has to use very short time step to integrate properly the
equations of motion. In contrast, Born-Oppenheimer MD has no electronic dynam-
ics. The electronic problem is treated through the time-independent Schro¨dinger
equation. Only the time scale given by nuclear motion is relevant. This allows us
to use a larger MD time step to integrate the equation of motion. However, Born-
Oppenheimer MD requires that the electronic structure problem has to be solved at
every MD step. This makes the method very expensive.
In 1985, Car and Parrinello [167] developed an ab initio MD scheme which com-
bines advantages of both Ehrenfest and Born-Oppenheimer MD. This so-called Car-
Parrinello MD allows the electronic wavefunction to be automatically minimized
when the nuclei are propagated like in the Ehrenfest dynamics, but with an increased
time step. Therefore, an explicit electronic minimization at each time step like in
Born-Oppenheimer MD is avoided. The Car-Parrinello MD is based on the idea
that fast electronic and slow nuclear motions can be adiabatically separated. Car
and Parrinello introduced an extended Lagrangian which includes both electronic
and nuclear degrees of freedom [167]. Each electronic degree of freedom (orbital)
is considered as a “fictitious” particle with a fictitious mass µ. Given a sufficiently
small value of the fictitious mass of the “electrons”, the total electronic wavefunction
can follow the nuclear motion adiabatically.
The Car-Parrinello Lagrangian is given by
LCP =
∑
I
1
2
MI ~˙R
2
I +
∑
i
1
2
µ 〈ϕ˙i |ϕ˙i 〉 − 〈ψ0|He |ψ0〉+ constraints. (3.40)
The first term is the nuclear kinetic energy, the second term is the kinetic energy
of the fictitious electrons. µ is the fictitious mass. {ϕi} is a set of orbitals used
to expand the total electronic wavefunction ψ0. 〈ψ0|He |ψ0〉 is the potential energy.
The last term enforces the orthogonality of the orbitals ϕi, which is not conserved as
in the case of the Ehrenfest scheme and therefore an orthonormalization is required
at each step of the Car-Parrinello MD. The corresponding equations of motion for
both nuclei and electrons are obtained from the Euler-Lagrange equations
d
dt
∂LCP
∂ ~˙RI
=
∂LCP
∂ ~RI
, (3.41)
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d
dt
δLCP
δϕ˙∗i
=
δLCP
δϕ∗i
, (3.42)
which give, respectively,
MI ~¨RI(t) = − ∂
∂ ~RI
〈ψ0|He |ψ0〉+ ∂
∂ ~RI
{constraints} , (3.43)
µϕ¨i(t) = − δ
δϕ∗i
〈ψ0|He |ψ0〉+ δ
δϕ∗i
{constraints} . (3.44)
The nuclei move at the physical temperature ∼ ∑
I
MI ~˙R
2
I whereas the electrons
move at a “fictitious temperature”∼∑
i
µ 〈ϕ˙i |ϕ˙i 〉. µ is the key parameter to control
the adiabatic separation between the nuclei and the electrons. The smaller µ is
the closer the instantaneous minimum energy 〈ψ0|He |ψ0〉 is to the exact Born-
Oppenheimer energy surface and vice versa. On the other hand, small µ means
small integration step. Therefore, in practice, a compromise between accuracy and
efficiency determines the choice of µ.
3.1.3.4 Density Functional Theory
Any electronic structure method such as density functional theory (DFT), Hartree-
Fock (HF), second-order many-body perturbation theory (MP2), or full configura-
tion interaction (FCI) can, in principle, be used in combination with the ab initio
molecular dynamics scheme. Here we focus only on the Hohenberg-Kohn-Sham den-
sity functional theory because the work in this thesis made extensive use of the
DFT-based Car-Parrinello molecular dynamics.
DFT is founded on the two Hohenberg-Kohn (H-K) theorems. Consider a system of
electrons moving under the influence of an external potential vn−e.
(i) The first H-K theorem states that the external potential vn−e is a unique func-
tional of the ground-state electron density ρ(~r). Because vn−e in turn deter-
mines the Hamiltonian He, full many-electron ground state is a unique func-
tional of ρ(~r). The total ground-state energy E0 can be written as a functional
of ρ(~r)
E0 [ρ (~r)] = T [ρ (~r)] + Ee−e [ρ (~r)] + En−e [ρ (~r)]
= FH−K [ρ (~r)] +
∫
ρ(~r)vn−e(~r)d~r, (3.45)
where
vn−e(~r) = − e
4piε0
∑
I
ZI∣∣∣~RI − ~r∣∣∣ +
e2
4piε0
∑
I<J
ZIZJ∣∣∣~RI − ~RJ ∣∣∣ . (3.46)
FH−K [ρ (~r)] is called the Hohenberg-Kohn functional. It is universal in the
sense that it does not depend on the external potential vn−e.
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(ii) The second H-K theorem states that for a trial electron density ρ˜ (~r), we always
have
E0 ≤ E0 [ρ˜(~r)] . (3.47)
Therefore, if we want to find E0, we need to search for the minimum of E0 [ρ(~r)].
Kohn-Sham approach
In order to find an explicit form for the functional FH−K [ρ (~r)], Kohn and Sham
assume that there is a reference system of non-interacting electrons (Kohn-Sham
electrons described by the orbitals ϕi) that feels an effective potential (Kohn-Sham
potential vks) such that its ground-state charge density is idential to that of the
interacting system that we are dealing with.
The advantage of this auxiliary system is that for the non-interacting electrons, we
know the exact solution to the equations of motion in terms of ϕi, which is the
Slater determinant ‖ϕi‖. The H-K functional FH−K is then written in terms of the
non-interacting system as
FH−K [ρ(~r)] =
−~2
2me
∑
i
∫
d~rϕ∗i (~r)∇2ϕi(~r)
+
e2
4piε0
∫
d~rd~r′ρ(~r)
1
|~r − ~r′|ρ(~r
′) + Exc [ρ(~r)] , (3.48)
where
ρ =
∑
i
|ϕi|2. (3.49)
The total electronic energy is given by
EKS [ρ(~r)] = FH−K [ρ(~r)] +
∫
d~rρ(~r)vn−e(~r)
= − ~
2
2me
∑
i
∫
d~rϕ∗i (~r)∇2ϕi(~r) +
e2
4piε0
∫
d~rd~r′ρ(~r)
1
|~r − ~r′|ρ(~r
′)
+
∫
d~rρ(~r)vn−e(~r) + Exc [ρ(~r)] , (3.50)
Exc [ρ (~r)] is called the exchange-correlation term, which is to be approximated. By
applying the variational principle to (3.50) with the condition (3.49), we can derive
a set of Kohn-Sham equations for the Kohn-Sham orbitals {ϕi}[
− ~
2
2me
∇2 + vks (ρ)
]
ϕi (~r) = εiϕi (~r) , (3.51)
where vks(ρ) is the Kohn-Sham potential
vks(ρ) = vn−e(~r) +
1
4piε0
∫
ρ (~r′)
|~r − ~r′|d~r
′ + vxc(ρ), (3.52)
and vxc(ρ) is the exchange-correlation potential, which is defined as the functional
derivative of Exc with respect to ρ(~r)
vxc [ρ(~r)] =
δExc [ρ(~r)]
δρ(~r)
. (3.53)
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In terms of Kohn-Sham DFT, the Car-Parrinello Lagrangian is written as
LCP =
∑
I
1
2
MI ~˙R
2
I +
∑
i
1
2
µ
∫
d~rϕ˙∗i (~r)ϕ˙i(~r)
− EKS [ρ(~r)] +
∑
i,j
Λij
[∫
d~rϕ∗i (~r)ϕi(~r)− δij
]
, (3.54)
where Λij are Lagrange multipliers.
Exchange-correlation functional
The exchange-correlation functional Exc [ρ(~r)] is unknown in the Kohn-Sham ap-
proach. Finding an approximation to this functional is critical to any application of
DFT. The very first approximation to Exc is the so-called “local density approxima-
tion” (LDA), which was introduced by Kohn and Sham [243, 244] and widely used
in physics. In this approximation, the exchange-correlation energy at each point is
assumed to be the same as that in a homogeneous electron gas with the same density
ELDAxc [ρ(~r)] =
∫
d~rρ(~r)εhomxc [ρ(~r)]
=
∫
d~rρ(~r)
{
εhomx [ρ(~r)] + ε
hom
c [ρ(~r)]
}
. (3.55)
For the homogeneous electron gas, the exchange part is known exactly [245, 246]
εx [ρ(~r)] = −3
4
(
3ρ(~r)
pi
) 1
3
. (3.56)
No analytical expression is known for the correlation part εc. Based on highly accu-
rate numerical quantum Monte-Carlo calculations of Cepperly et al. in 1980, many
different analytical expressions of εc have been presented based on sophisticated in-
terpolation schemes. The most widely used forms of εc are the one developed by
Vosko, Wilk and Nusair [247] as well as the one given by Perdew and Wang [248].
For chemical applications, LDA is usually insufficient. This has led to the develop-
ment of generalized-gradient approximations (GGAs), in which also the density gra-
dient ~∇ρ(~r) is taken into account in the expression of Exc. In GGAs, the exchange-
correlation functional is written as
EGGAxc [ρ(~r)] =
∫
d~rρ(~r)εxc
[
ρ(~r),
∣∣∣~∇ρ(~r)∣∣∣]
= EGGAx [ρ(~r)] + E
GGA
c [ρ(~r)] (3.57)
A very popular GGA functional is given by a combination of the Becke exchange
functional and the Lee-Yang-Parr correlation functional (BLYP) [195, 196]. The
Becke exchange functional is given by
EGGAx [ρ] = E
LDA
x [ρ]− β
∫
ρ(~r)4/3
x3
1 + 6β sinh−1 x
d~r, (3.58)
where
x =
∣∣∣~∇ρ(~r)∣∣∣
ρ(~r)4/3
(3.59)
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The parameter β is determined by a fit on the exact HF data and was fixed by Becke
to be 0.0042 au.
The Lee, Yang and Parr correlation function was derived from the Colle-Salvetti
formula to calculate the correlation energies from HF second order density matrix
EGGAc [ρ] = −a
∫
1
1 + ρ1/3
(
ρ+ bρ−2/3
[
CFρ
5/3 − 2tW +
(
1
9
tW +
1
18
∇2ρ
)]
e−ρ
1/3
)
d~r,
(3.60)
where
CF =
3
10
(
3pi2
)2/3
, (3.61)
tW =
1
8
|∇ρ|2
ρ
− 1
8
∇2ρ, (3.62)
and a = 0.04918, b = 0.132.
3.1.3.5 Basis set
In practical implementations for solving the Kohn-Sham equations (3.51), the Kohn-
Sham orbitals {ϕi(~r)} are expanded as a linear combination of basis functions with
well-known behaviors and with which it is possible to perform mathematical opera-
tions very fast on a computer
ϕi(~r) =
∑
l
cilfl
(
~r;
{
~RI
})
. (3.63)
Localized basis sets
In quantum chemistry, the two most frequently used basis functions are the Slater-
type basis functions
fSl = N
S
l r
mx
x r
my
y r
mz
z exp [−ζm |~r|] , (3.64)
and the Gaussian-type basis functions
fGl = N
G
l r
mx
x r
my
y r
mz
z exp
[−αmr2] , (3.65)
where Nm, ζm and αm are constants and kept fixed during an electronic structure
calculation, and only the coefficients cil need to be optimized.
Plane wave basis set and pseudopotentials
In periodic systems, it is more convenient to use plane waves as a basis set. Plane
wave functions are defined as
fPWG =
1√
V
ei
~G~r, (3.66)
where V is the volume of the periodic cell, ~G is the reciprocal lattice vector.
According to Bloch’s theorem, the eigenfunctions of periodic systems can be written
as
ϕi,~k(~r) = e
i~k~rui,~k(~r), (3.67)
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where ~k is a wave vector in the first Brillouin zone of the reciprocal lattice. ui,~k(~r)
is a cell-periodic function
ui,~k(~r +
~R) = ui,~k(~r), (3.68)
which can be expanded as a Fourier series
ui,~k(~r) =
1√
V
∑
~G
Ci,~k(
~G)ei
~G~r. (3.69)
Eq. (3.67) then becomes
ϕi,~k(~r) =
1√
V
∑
~G
ci,~k(
~G)ei(
~G+~k)~r. (3.70)
A further approximation can be introduced to minimize the size of the plane wave
basis set: the so-called pseudopotential approximation [249, 250, 251]. This approxi-
mation is based on the observation that core electrons, i.e. the electrons close to the
nuclei that are not involved in the chemical reactions, are somewhat unaffected by
the chemical environment. Therefore, it is sufficient to consider just the valence elec-
trons, whereas the core ones are replaced by pseudopotentials to take into account
their effect in the motion of the valence electron. The valence electron wavefunction
can then be replaced by pseudo wavefunction |ψps〉, which now varies smoothly in
the core region (Fig. 3.1). As a consequence, the number of plane waves needed to
expand the wavefunctions is greatly reduced.
The pseudo valence states can be found by solving the all-electron Schro¨dinger equa-
tion for an atom [
Hˆ + Vˆnl
]
|ψps〉 = E |ψps〉 , (3.71)
where Hˆ is all-electron Hamiltonian of an atom, Vˆnl is an energy-dependent non-local
potential
Vˆnl =
∑
i∈core
(E − Ei) |χi〉 〈χi.| (3.72)
|χi〉 and Ei are eigenstates and eigenvalues of the core-electron states, respectively.
Since the additional potential Vˆnl is repulsive, sum of Vˆnl with the strongly attractive
Coulomb potential VˆCou results in a much weaker pseudopotential [251, 252]
Vˆ PS = VˆCou +
∑
i∈core
(E − Ei) |χi〉 〈χi.|. (3.73)
Pseudopotentials are constructed from ab initio calculations for isolated atoms, e.g.,
by solving the Kohn-Sham equations. For atoms, due to the spherical symmetry, the
wavefunctions can be written as a product of a radial function and a spherical har-
monic. The Kohn-Sham equations then reduce to one-dimensional differential equa-
tions for the radial function. Serveral schemes for generating pseudopotentials have
been proposed. In this thesis, we have used the “Norm-conserving” pseudopotentials
derived from the Martins-Troullier (MT) scheme [197], in which the pseudopotentials
have to satisfy the following conditions:
(i) The lowest pseudo wavefunction should not contain any node.
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(ii) The eigenvalues of both real and pseudo wavefunctions must be the same
(iii) The radial pseudo wavefunction with an angular momentum l should be equal
to the radial all-electron wavefunction outside a cut-off radius rc.
(iv) The integrated charge inside rc must be the same for both wavefunctions.
Figure 3.1 Schematic diagram of the relationship between all-electron and pseu-
dopotentials and wavefunctions as well as real and pseudopotentials,
adapted from [253].
3.1.4 Force field-based molecular dynamics
Due to a large number of atoms (thousands of atoms) in a typical biomolecular
systems, full ab initio molecular dynamics is not feasible. Therefore, force fields
are usually used to approximate the interatomic potential energy. In this approach,
the potential energy of the atoms is approximated by a simple analytical function
(force field) of the atomic coordinates. In this way, the need to solve the quantum
electronic problem can be avoided.
Force fields contain a set of adjustable parameters, which have to be fitted to data
obtained from experiments or high-level quantum mechanical calculations. There are
various types of force fields used in biomolecular simulations with different functional
forms and parameter sets, such as AMBER [173], GROMOS [189], CHARMM [254],
etc.
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The AMBER force field [173] which has been used in this work has the following
functional form
UFF =
∑
bonds
KR (R−Req)2 +
∑
angles
Kθ (θ − θeq)2 +
∑
dihedrals
Vn
2
[1 + cos(nφ− γ)]
+
∑
I<J
qIqJ
εRIJ
+
∑
I<J
σIJ
[(
Rmin I,J
RIJ
)12
− 2
(
Rmin I,J
RIJ
)6]
. (3.74)
KR, Kθ and Vn are bond, angle and dihedral force constants, respectively. R and Req
are bond length and its equilibrium value, respectively. θ and θeq are the angle and
its equilibrium value, respectively. n, φ and γ are the number of barriers, dihedral
angle and phase, respectively. RIJ is the distance between atom I and atom J . qI
is the partial charge of atom I. ε is the dielectric constant. Rmin I,J and σIJ are the
equilibrium distance and the well depth of the van der Waals interaction potential,
respectively.
3.1.5 Hybrid Car-Parrinello/molecular mechanics (QM/MM) molec-
ular dynamics
QM/MM MD is the method of choice for studies of chemical reactions and for
accurate descriptions of metallic complexes in large biomolecular systems [172, 170,
171]. In this approach, the system of interest is partitioned into two parts: one is
treated at quantum mechanical level (QM part), and the other one treated with the
molecular mechanics force fields (the MM part).
The Car-Parrinello MD scheme (Eq. 3.54) can also be extended to deal with
QM/MM approach. The corresponding extended Lagrangian is [169]
LQM/MM = LCP − EMM − EQM/MM
=
1
2
∑
I
MI ~˙R
2
I +
1
2
µ
∑
i
∫
d~rϕ˙∗i (~r)ϕ˙i(~r)− EKS [ρ(~r)]
+
∑
ij
Λij
[∫
d~rϕ∗i (~r)ϕi(~r)− δij
]
− EMM − EQM/MM, (3.75)
where EMM is the force field-based energy function describing the MM part, EQM/MM
is the coupling term between QM and MM parts.
In our work, EMM is given by the AMBER force field in Eq. (3.74)
EMM = U
FF (3.76)
The QM/MM coupling term EQM/MM can be expanded in three terms:
EQM/MM = E
ele
QM/MM + E
vdw
QM/MM + E
bonded
QM/MM. (3.77)
The first term in the right-hand side is the electrostatic coupling between the quan-
tum charge distribution and the classical point charges. The second and third terms
describe the van der Waals and bonded interactions between QM and MM atoms,
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respectively. Covalent bonds cut by the QM/MM boundary are saturated by cap-
ping hydrogen atoms. The bonded interactions between QM and MM regions, i.e.
bond stretching, angle bending and dihedral torsions are described by the force field.
The same holds for van der Waals interaction between QM and MM atoms.
The electrostatic coupling term EeleQM/MM reads
EeleQM/MM =
∑
i∈MM
qi
∫
d~rρ(~r)vi (|~r − ~ri|) (3.78)
where qi are the partial charges at ~ri and vi (|~r − ~ri|) is a modified Coulomb potential.
This potential is modified at short range to avoid the so-called electron spill-out
phenomenon, i.e. the unphysical accumulation of charge density at the boundary
of the QM box due to the presence of classical positive charges of the nearby MM
region [169]
vi(~r) =
rnci − rn
rn+1ci − rn+1
. (3.79)
In Eq. (3.79), n is usually fixed to 4 and rci is the covalent radius of atoms. vi(r)
is chosen such that it saturates to 1/r at large distance and goes smoothly to a
constant value for small r (see Fig. 3.2).
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Figure 3.2 Schematic representation of Coulomb and modified Coulomb poten-
tials.
The influence of rc’s on the pair correlation function between QM and MM atoms
was probed by performing a QM/MM simulations of a quantum water molecule
in a box of classical water [169]. It was shown that the QM/MM pair correlation
function were consistent with the full quantum calculation when rci is chosen close
to the covalent radius (i.e. ∼ 0.4 A˚ for hydrogen and ∼ 0.7 A˚ for oxygen).
Because the calculation of the integrals in Eq. (3.78) is computationally expensive,
they are calculated only for the MM atoms within a cut-off radius (∼ 5 A˚) from
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the interface. Beyond this first shell and within a second cut-off radius (∼ 10 A˚),
the electrostatic interactions are calculated using D-RESP (Dynamically Generated
Potential Derived Charge) charge scheme [168]. In this approach, a set or point
charges for QM atoms are fitted “on the fly” in each step of QM/MM simulations so
as to reproduce the electrostatic potential evaluated at the positions of MM atoms
close to the QM region. These point charges then interact with the point charges
of MM atoms within the second shell. Finally, the electrostatic interactions are
calculated between a multipolar expansion of the QM charge density and the MM
classical point charges contained in the outer most region (> 10 A˚) [169].
3.1.6 Force matching procedure
Although QM/MM method can provide very accurate description of metal coor-
dination structures in large biomolecules, the typical time scales are rather short
(≤ 100 ps) with respect to the time scales of relevant biological phenomena. To
study global conformational changes of large systems, extensive classical MD simu-
lations are, therefore, mandatory. This issue can be addressed by developing a set
of force field parameters for the metal moieties in the biomolecules. Then, long time
classical MD simulations can be performed based on these newly derived parameters.
The force matching procedure [174, 175] based on QM/MM trajectories offers an
accurate and elegant method for the force field parameterization. In this approach,
a QM/MM simulation is performed for a given system, which is divided into two
parts: one treated at the quantum mechanical level (the QM part) and the other at
the force field level (the MM part). The fragment that needs to be parameterized is
included in the QM part. A set of snapshots is selected along the QM/MM trajectory.
This set is used as reference structures for the force matching procedure. The ab
initio forces acting on the QM atoms together with the electrostatic potential and
field at positions of the nearby MM atoms are stored for each selected conformation.
First a set of point charges {qI} for the atoms in the QM region is derived. This set
is fitted to reproduce both the electrostatic potential and the electrostatic field that
the QM part exerts on the surrounding MM atoms. The following target function
is minimized to obtain {qI}
χ2 =
L∑
l
( ∑
J∈NN
wv(V MMJl − V ρJl)2 +
∑
J∈NN
wE
∥∥∥ ~EMMJl − ~EρJl∥∥∥2 + ∑
I∈QM
wH(qI − qHIl )2
)
+ wQ
(
Qtot −
∑
I∈QM
qI
)2
. (3.80)
The index l runs over L conformations. The index J runs over all MM atoms that
interact explicitly with the quantum electron density in the QM/MM calculations
(here called NN atoms). The index I runs over all QM atoms. V ρJl and
~EρJl are the
electrostatic potential and the electrostatic field, respectively, due to the presence
of the QM charge density, and felt by classical atom J in configuration l. V MMJl
and ~EMMJl are the potential and field generated by the {qI} set. Restraining the
{qI} set so as to reproduce both the electrostatic potential and the electrostatic field
has been shown to provide better results than reproducing only the electrostatic
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potential [174]. The third term restrains the set of charges {qI} to the Hirshfeld
charge values qHIl [272]. The last term restrains the total charge of the {qI} set to
the correct value Qtot.
Then, the {qI} and the van der Waals parameters (taken from a standard force field
such as AMBER [173]) are used to calculate the total non-bonded forces acting on
the QM atoms. These forces are subtracted from the total force, yielding a set of
bonded forces
~FQMbonded = ~FQM − ~FMMnon−bonded . (3.81)
Finally, the force field bonded parameters, including bonds, angles, and torsions for
the atoms in the QM region are obtained through a least squares fit to the bonded
ab initio forces.
σ2 =
L∑
l=1
∑
I∈QM
∥∥∥~FMMbondedlI − ~FQMbondedlI ∥∥∥2. (3.82)
The parameters are fitted to obtain the smallest average error over all the reference
frames, extracted from QM/MM simulations at finite temperature.
3.1.7 Ewald summation
In molecular dynamics simulations of biomolecules, the computation of non-bonded
interactions, e.g., the fourth and fifth terms in Eq. (3.74) is the most expensive
because the sums are over all the pairs of atoms. Furthermore, under the periodic
boundary conditions, these sums extend over an infinite number of periodic images.
The simplest way to avoid summing over all the atom pairs is to truncate the poten-
tial at a cut-off distance Rc. In such a case, one can show that [256] the contribution
from the tail of the potential U(R) can be estimated (in 3D) using
U tail =
Nn
2
∞∫
Rc
4piR2U(R)dR, (3.83)
where n is the average number density. The equation above implies that the tail
contribution to the potential energy diverges, unless the potential energy U(R) de-
cays faster than R−3. Therefore, we can safely apply the truncation method for the
van der Waals term (the fifth term in Eq. (3.74)) which decays as R−6, but not for
the Coulombic term (the fourth term in Eq. (3.74)) which decays as R−1.
The Ewald summation method offers a fast way to compute the long-range Coulom-
bic interaction in periodic systems as the fourth term in Eq. (3.74). Let us suppose
that the system consists of N charged particles in a cubic box of size L, subject to
periodic boundary conditions. The total Coulomb energy of the system is
U =
1
2
∑′
~n
∑
IJ
qIqJ∣∣∣~RIJ + ~n∣∣∣ , (3.84)
where qI is the charge of particle I. The prime on the summation indicates the sum
is over all periodic images ~n and over all particles I, J , except I = J if ~n = 0.
The above sum extends over an infinite number of periodic images. Moreover, it
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is conditionally convergent, which means that the result depends on the order of
summation [255]. Therefore, it cannot be used to compute electrostatic energy in
molecular dynamics simulations.
In the Ewald summation method [263, 264], the charge distribution ρ(~R) of the
system is represented by an infinite set of point charges qI , which can be written in
terms of delta function as
ρI
(
~R
)
= qIδ
(
~R− ~RI
)
. (3.85)
At each point charge, an isotropic Gaussian charge distribution of equal magnitude
but opposite sign:
ρGI
(
~R
)
= qI
(
2√
pi
)3
e−α
2|~R−~RI|2 (3.86)
is then added. This smeared charge screens the interaction between the point
charges, so that the interaction of the screened charge distribution
ρSI
(
~R
)
= ρI
(
~R
)
+ ρGI
(
~R
)
(3.87)
becomes short range:
US =
1
2
∑
~n
∑
IJ
qIqJ∣∣∣~RIJ + ~n∣∣∣erfc
(
α
∣∣∣~RIJ + ~n∣∣∣), (3.88)
where
erfc(x) =
2√
pi
x∫
0
e−y
2
dy, (3.89)
is the complementary error function. Therefore, US can be approximated by trun-
cation.
Finally, a Gaussian charge distribution of opposite sign −ρGI
(
~R
)
must be added
to recover the original charge distribution ρI
(
~R
)
. The interaction energy of this
Gaussian distribution can be expressed as a lattice sum in the reciprocal space minus
a self term:
Um =
1
2piV
∑
IJ
qIqJ
∑
~k 6=0
1
k2
(
e−
k2
4α2 ei
~k ~RIJ
)
− α√
pi
∑
I
q2I , (3.90)
where
~k = 2piL−1 (lx, ly, lz) , (3.91)
and lx, ly and lz are integers. Due to the presence of the exponential factor the
lattice sum can be well approximated by a finite one.
3.1.8 Molecular dynamics in NPT ensemble
The trajectory generated by integrating the Newton’s second equation (3.27) cor-
responds to a sampling on an NVE ensemble. However, most experiments are per-
formed at constant pressure and constant temperature conditions. Therefore, it is
essential to be able to perform simulations under the same NPT condition. This
requires introducing thermostat and barostat algorithms to control the temperature
and pressure, respectively.
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3.1.8.1 Thermostats
Berendsen thermostat
Berendsen thermostat [265] is a weak coupling method, in which the temperature of
the system is kept close to a target by the equation
dT
dt
=
1
τT
[T0 − T (t)] , (3.92)
where T is the instantaneous value of the temperature and τT is the coupling time.
The instantaneous temperature T of the system with 3N degrees of freedom is related
to the kinetic energy through the equation
Ekin =
∑
I
MI ~˙R
2
I(t) =
3
2
NkBT (t). (3.93)
Therefore, to change the temperature by an amount δT at each finite time step δt
we have to change kinetic energy by an amount
δEkin =
3
2
NkBδT =
3
2
NkB
1
τT
[T − T (t)] δt. (3.94)
This change in kinetic energy can be achieved by rescaling the velocities by a factor
λ, which is related to δEkin as
δEkin =
∑
I
MI
(
λ2 − 1) ~˙R2I(t). (3.95)
From Eqs. (3.93), (3.94) and (3.95) we obtain
λ =
√
1 +
δt
τT
(
T0
T
− 1
)
. (3.96)
The factor λ is used to scale the velocities at each integration step to relax the
temperature towards the target value T0. The relaxation rate is controlled by the
coupling constant τT .
Nose-Hoove thermostat The approach of Nose [199] is based on the use of ex-
tended Lagrangian. Nose introduce an extra degree of freedom S to the Lagrangian
of the classical N -body system
LNose =
1
2
N∑
I=1
MIS
2 ~˙R2I − U
({
~RI
})
+
Q
2
S˙2 − L
β
lnS, (3.97)
where L is a constant, Q is an effective mass associated with S. The conjugate
momenta of ~RI and S are given by
~PI ≡ ∂LNose
∂ ~˙RI
= MIS
2 ~˙RI (3.98)
~PS ≡ ∂LNose
∂S˙
= QS˙ (3.99)
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Hence, the Hamiltonian of the extended system of N particles and the additional
degree of freedom S is
HNose =
∑
I
~P 2I
2MIS2
+ U
({
~RI
})
+
P 2S
2Q
+ L
lnS
β
. (3.100)
The corresponding partition function of the microcanonical (NVE) ensemble is
ZNose =
1
N !
∫
dPSdSd~Pd~Rδ (E −HNose). (3.101)
Let us define the scaled momenta
~P ′ =
~P
S
. (3.102)
ZNose becomes
ZNose = C
1
N !
∫
d~P ′d~R exp
[
−β 3N + 1
L
H
(
~P ′, ~R
)]
, (3.103)
where
H
(
~P ′, ~R
)
=
∑
I
~P ′
2
I
2MI
+ U
({
~RI
})
. (3.104)
If we choose L = 3N + 1, then ZNose corresponds to the partition function of the
canonical (NVT) ensemble of the system with the degrees of freedom
{
~P ′I
}
,
{
~RI
}
.
Therefore, we can interpret ~P ′ as the physical momenta while ~P as the virtual
momenta. If we denote all the physical variables as primed and virtual momenta as
unprimed, we have the following relations
~R′ = ~R,
~P ′ =
~P
S
,
S ′ = S,
∆t′ =
∆t
S
. (3.105)
From the Hamiltonian (3.100), one can derive the equations of motion for the virtual
variables
d~RI
dt
=
∂HNose
∂ ~PI
=
~PI
MIS2
, (3.106)
d~PI
dt
= −∂HNose
∂ ~RI
= −
∂U
({
~RI
})
∂ ~RI
, (3.107)
dS
dt
=
∂HNose
∂PS
=
PS
Q
, (3.108)
dPS
dt
= −∂HNose
∂S
=
(∑
I
~P 2I
MIS2
− L
β
)
/S, (3.109)
3.1. Molecular dynamics 37
or for the physical variables, these equations of motion become
d~R′I
dt′
=
~P ′I
MI
, (3.110)
d~P ′I
dt′
= −
∂U
({
~R′I
})
∂ ~R′I
−
(
S ′P ′S
Q
)
~P ′I , (3.111)
1
S
dS ′
dt′
=
S ′P ′S
Q
, (3.112)
d
(
S′P ′S
Q
)
dt′
=
(∑
I
~P ′
2
I
MI
− L
β
)
/Q. (3.113)
Hoover [200] further simplified these equations by introducing the thermodynamic
friction coefficient
ξ =
S ′P ′S
Q
. (3.114)
The equations of motions (3.110)–(3.113) become, after dropping the primes
~˙RI =
~PI
MI
, (3.115)
~˙PI =
∂U
({
~RI
})
∂ ~RI
− ξ ~PI , (3.116)
S˙
S
=
d lnS
dt
= ξ. (3.117)
ξ˙ =
(∑
I
~P 2I
MI
− L
β
)
/Q, (3.118)
3.1.8.2 Barostats
In a molecular dynamics simulation of a periodic system in a box, the isotropic
pressure p is defined as the trace of the pressure tensor p
p =
1
3
Tr (p) . (3.119)
p is calculated by the Clausius virial theorem
p =
2
V
(EKin − Ξ) , (3.120)
where V is the box volume, EKin is the kinetic energy and Ξ is the inner virial tensor
Ξ = −1
2
∑
I<J
~RIJ ~FIJ . (3.121)
38 3. Methods
Pressure control during a simulation can be achieved through a change in the inner
virial tensor by rescaling the inter-particle distances RIJ .
In the Andersen barostat approach [266], the coordinates
{
~RI
}
are replaced by
scaled coordinates
{
~R′I
}
defined as
~R′I =
~RI
V 1/3
. (3.122)
Consider a new Lagrangian, in which the volume V appears as an additional dy-
namical variable
LAn =
1
2
V 2/3
∑
I
MI ~˙R
′2
I −
∑
I<J
U
(
V 1/3R′IJ
)
+
1
2
µV˙ 2 − p0V. (3.123)
The first two terms on the right hand side are the Lagrangian of the unscaled system,
the third term is the kinetic energy for the motion of V , and the fourth term repre-
sents a potential energy associated with V . p0 and µ are constants, whose physical
meaning is represented by the target pressure and the pressure coupling constant,
respectively.
From the Lagrangian (3.123), the corresponding Hamiltonian and hence the equa-
tions of motion for the scaled variables can be derived. Finally, mapping back to the
unscaled variables
{
~RI
}
, we get
d~RI
dt
=
~PI
MI
+
1
3
~RI
d lnV
dt
, (3.124)
d~PI
dt
= −
∑
I<J
~RIJU
′ (RIJ)− 1
3
~PI
d lnV
dt
, (3.125)
µ
d2V
dt2
= p0 +
[
2
3
∑
I
~P 2I
2MI
− 1
3
∑
I<J
~RIJU
′ (RIJ)
]
/V. (3.126)
Parrinello and Rahman [202] in 1981 extended the Andersen barostat to allow the
simulation box to change its shape. The cell can have an arbitrary shape and its
volume is completely determined by three vectors ~a, ~b and ~c
V = deth = ~a ·
(
~b× ~c
)
, (3.127)
where h is a 3 matrix, whose columns are the three vectors ~a, ~b and ~c.
The position ~RI of a particle can be written in terms of h and a column vector ~SI
with components ξI , ηI and ζI as
~RI = h~SI = ξI~a+ ηI~b+ ζI~c, (3.128)
with 0 ≤ ξI , ηI , ζI ≤ 1. The squared distance between particle I and J is given by
R2IJ = S
T
I GSJ , (3.129)
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where G is the metric tensor
G = hTh. (3.130)
Using notations above, the Lagrangian can then be written as
LPR =
1
2
∑
I
MI S˙
T
I GS˙I −
∑
I<J
U (RIJ) +
1
2
µTr
(
h˙T h˙
)
− p0V. (3.131)
The corresponding equations of motion can be derived similarly to the isotropic case
from Andersen.
3.1.9 Replica exchange with solute tempering
Replica exchange molecular dynamics method (Usually it is called REM) [267, 268,
269] has been widely used to accelerate conformational sampling of complex systems,
such as biomolecules. However, the number of replicas increases with the square root
of the number of degrees of freedom [268, 270], which limits its applications for large
systems. To overcome this problem, Liu et al. [176] proposed a so-called “replica
exchange with solute tempering” (REST) variant of REM, which is able to reduce
significantly the number of replicas.
This scheme is based on the observation that the simulation box of most biomolecular
systems consists of relatively small solute molecules (proteins, DNA...) and a large
number of solvent molecules. However, the main interest is usually in the solute
conformations. Therefore, REST aims at enhancing only the dynamics of the solute
molecules.
In a standard REM simulation, multiple replicas of the same system are prepared.
Each replica has different temperature and/or Hamiltonian and is sampled indepen-
dently with the canonical ensemble MD simulations for some time. Then, with a
certain frequency, exchange between neighboring replicas is attempted with some
probabilities. These exchange probabilities are determined so that the ensemble of
each replica obeys the Boltzmann distribution.
In case the replicas differ only in the Hamiltonian, the Boltzmann distribution for
each replica is given by
Pi(Xi) = Z
−1
i exp [−βEi(Xi)] , (3.132)
where Ei is the energy and Zi is the partition function of replica i. The exchange
probability W (i→ j) between replica i and j is determined from the detailed bal-
ance condition
Pi(Xi)Pj(Xj)W (i→ j) = Pi(Xj)Pj(Xi)W (j → i), (3.133)
which gives the ratio of the transition probabilities
W (i→ j)
W (j → i) = exp(−∆), (3.134)
with
∆ = β [Ei(Xj) + Ej(Xi)− Ei(Xi)− Ej(Xj)] . (3.135)
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If the Metropolis criterion is applied, the acceptance probability is chosen as
W (i→ j) =
{
1 if∆ ≤ 0
exp(−∆) if∆ > 0. (3.136)
In the REST variant proposed by Liu et al. [176], the system of interest (e.g. protein
solvated in water) is therefore divided into two parts: the protein molecule (denoted
by p) and water molecules (denoted by w). The potential energy of each replica used
to enhance sampling is scaled such that the protein molecule in different replicas has
different effective temperature while the solvent’s effective temperature is the same
in all replicas. The potential energy can be divided into three terms
V = Vpp + Vpw + Vww, (3.137)
where the first term represents the energy of the protein, the second one the in-
teraction energy between the protein and water, and the third, the interaction of
water molecules with each other. The system of interest is usually chosen to be the
lowest replica, i.e. the protein solution at the inverse temperature β0 =
1
kBT0
with
the energy potential given by Eq. (3.137). The energy potential for the highest
temperature replica is given by
VH =
βH
β0
Vpp +
√
βH
β0
Vpw + Vww, (3.138)
where βH is the inverse of the highest effective protein temperature. The energy
potentials for the intermediate replicas are defined as the linear combination of the
two-end potentials defined above
Vi = (1− λi)V + λiVH
=
[
(1− λi) + βH
β0
λi
]
Vpp +
[
(1− λi) +
√
βH
β0
λi
]
Vpw + Vww, (3.139)
where λi is related to the effective inverse temperature βi of replica i through the
formula
λi =
βi − β0
βH − β0 . (3.140)
The energy potentials of all the replicas are now completely defined by equations
(3.137)-(3.139). One can directly use the Hamiltonian replica exchange routine of
GROMACS program [203], which is based on the λ–dynamics to perform REST
simulations. The number of replicas and values of effective temperature can be
estimated using the approach of ref. [271], in which only the number of protein’s
atoms is taken into account. The relation (3.140) is then used to determine the
values of the coupling constants λi.
3.2 Computational spectroscopy
In this thesis, extensive comparison with experimental spectroscopic properties is
made. Here, we present the theoretical framework of the spectroscopy calculations
carried out in this work.
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3.2.1 NMR chemical shifts
In NMR experiments of a solute in aqueous solution, the sample is exposed to
an external magnetic field ~Bext. This magnetic field induces an electronic current
~j(~r). It, in turn, produces an additional inhomogeneous magnetic field ~Bind at the
positions of sample’s nuclei. The latter field is sensitive to the electronic density
and thus different for different nuclei depending on their chemical environment.
Therefore, it determines the resonance frequencies of the nuclear spins measured in
an NMR experiment [273] by irradiating the sample with an electromagnetic pulse.
The chemical shielding tensor
↔
σ is defined as the proportionality tensor factor be-
tween the induced and the external magnetic field at the positions of the nuclei
↔
σ (~r) =
∂ ~Bind (~r)
∂ ~Bext
. (3.141)
NMR experiments of biomolecules in solution measure isotropic shieldings. This can
be calculated as the trace of the shielding tensor
↔
σ
σ =
1
3
Tr
(↔
σ
)
. (3.142)
The shielding tensor is sensitive to the local electronic density and thus to the
chemical bonding environment. The resonance condition is given by
∆E = hν = gHµH (1− σ) ~Bext. (3.143)
∆E is the resonance energy; ν is the corresponding frequency, h is Planck’s constant.
gH and µH are the nuclear g-factor and the nuclear magneton, respectively. The
chemical shift δ of a given sample is defined with respect to a reference frequency
δ =
vsample − vreference
vreference
× 106 [ppm] , (3.144)
where νsample is the frequency of a nucleus in the sample, and νreference is that of the
reference system.
From this discussion it is clear that the key quantity for NMR chemical shift calcu-
lations is the local magnetic field ~Bind that is induced by the total electronic current
~j(~r). It reads
~Bind (~r) =
µ0
4pi
∫
d3~r′
~r′ − ~r
|~r′ − ~r|2 ×
~j (~r′), (3.145)
where µ0 is the permeability in vacuum. The total electronic current ~j(~r) can be
calculated using first principles density functional perturbation theory [208]. The
Kohn-Sham orbitals are expanded in powers of the external magnetic field
φi = φ
(0)
i +B
extφ
(1)
i +
(
Bext
)2
φ
(2)
i + ... (3.146)
They minimize the total density functional
EtotKS = EKS
[
φ
(0)
i +B
extφ
(1)
i + ...
]
+ εpert
[
φ
(0)
i +B
extφ
(1)
i + ...
]
, (3.147)
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where EKS is the unperturbed Kohn-Sham density functional in Eq. (3.50). The
corresponding unperturbed effective Kohn-Sham Hamiltonian is
HKS = − ~
2
2me
∇2 + vks(ρ), (3.148)
where vks is the Kohn-Sham potential given by Eq. (3.52).
The external magnetic field can be written as
~Bext = ~∇× ~A (~r) , (3.149)
where ~A(~r) is the vector potential. The vector potential is not uniquely defined since
the gradient of any scalar function can be added without changing ~Bext. In the case
of a homogeneous magnetic field (as in the case of NMR experiments), ~A can be
conveniently chosen as [273]
~A (~r) = −1
2
(
~r − ~Rgo
)
× ~Bext, (3.150)
where ~Rgo is the gauge origin of the vector potential ~A(~r), i.e. the center of the
vector potential. This is an arbitrary parameter.
The main point in defining ~A(~r) is that the introduction of the external magnetic field
~Bext is equivalent to replacing the momentum operator ~p = −i~~∇ in the unperturbed
Kohn-Sham Hamiltonian (3.148) by ~p − e
c
~A (~r), where c is the speed of light. This
leads to a perturbation term in the Hamiltonian at the first order in the field strength
(paramagnetic term), − e
mec
~p · ~A (~r) and one at the second order (diamagnetic term),
e2
2mec2
~A (~r) · ~A (~r):
HtotKS = HKS +H
pert, (3.151)
with
Hpert = − e
mec
~p · ~A (~r) + e
2
2mec2
~A (~r) · ~A (~r) . (3.152)
Then, the perturbation functional energy εpert reads
εpert =
∑
i
〈
φi
∣∣Hpert∣∣φi〉 = ∑
i
e2
2mec2
〈
φ
(0)
i
∣∣∣ ~A (~r) · ~A (~r)∣∣∣φ(0)i 〉
− e
mec
(〈
φ
(1)
i
∣∣∣~p · ~A (~r)∣∣∣φ(0)i 〉+ 〈φ(0)i ∣∣∣~p · ~A (~r)∣∣∣φ(1)i 〉) , (3.153)
in which φ
(0)
i are the ground state Kohn-Sham orbitals and φ
(1)
i are the first order
corrections.
The first order perturbation gives rise to a correction φ(1) to the electronic ground
state in Eq. (3.146). This correction is responsible for the induced current, which
is obtained from the functional Eq. (3.153) as a sum of a dia- and a paramagnetic
term [208, 209]:
~j (~r) =
e2
me
~A (~r)
∑
i
∣∣∣φ(0)i (~r)∣∣∣2
− e
me
∑
i
[〈
φ
(1)
i |~p|φ(0)i
〉
−
〈
φ
(0)
i |~p|φ(1)i
〉]
. (3.154)
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Both contributions depend individually on the choice of the gauge. To address the
implications resulting from the ambiguity in such choice, several approaches have
been developed, see e.g. [273]. Here, we use the so-called “~Rgo = ~r” variant of the
“Continuous Set of Gauge Transformations” (CSGT) method [274], which is most
appropriate for plane-wave based calculations. For each point in space ~r, the current
density (Eq. 3.154) is calculated by setting ~Rgo equal to ~r.
For heavy atoms such as Pt, it is essential to take into account relativistic effects be-
cause the core electrons (close to the nucleus) in these atoms move at a considerable
fraction of the speed of light. In this thesis, we have used the Zero Order Regular Ap-
poximation (ZORA) appoach to include the relativistic correction in the calculations
of Pt NMR shielding constants. In the ZORA approach, the effective one-electron
Kohn-Sham Hamiltonian (3.148) is replaced by the relativistic Hamiltonian for an
electron:
HZORAKS = vks + ~p
c2
2c2 − vks ~p+
c2
2c2 − vks
↔
σ
(
~∇vks × ~p
)
, (3.155)
where vKS is the effective one-electron Kohn-Sham potential given in Eq. (3.52),
↔
σ
is the Pauli matrix, c is the speed of light. The magnetic field can be then included
in the same way, i.e., by means of the substitution
~p→ ~p− e
c
~A (~r) . (3.156)
3.2.2 Extended X-ray absorption fine structure (EXAFS)
EXAFS spectroscopy probes the local environment of metal ions in biological systems
[275, 220]. It provides detailed local structural information such as interatomic
distances and coordination numbers. In an EXAFS experiment, an absorbed X-ray
photon liberates an electron from a core level resulting in an absorption edge in the
spectrum. The energies of the edges are unique to the type of atom. Well above
the absorption edge (≥ 30 ev), oscillatory wiggles arise from higher order multiple
scattering. In fact, the ejected photoelectron wave function scatters from the atoms
surrounding the absorbing atom, thereby creating interferences between the outgoing
and scattered waves. Thus, the signal is sensitive to the short-range order in the
system under investigation. These quantum interferences cause an energy-dependent
variation of the X-ray absorption coefficient µ, a measurable quantity. The EXAFS
function χ of a specific atom is then defined as the normalized, oscillatory part of
the X-ray absorption above the absorption edge of that atom
χ (E) =
µ (E)− µ0 (E)
µ0 (E)
, (3.157)
where E is the energy of the photoelectron, defined with reference to a core level Ei
from which the electron is liberated
E = ~ω + Ei. (3.158)
~ω is the energy of X-ray photon. µ0(E) is the absorption coefficient of the isolated
atom. Eq. (3.157) is the theoretical definition for the EXAFS, in which µ0(E) can be
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calculated theoretically [276] but it is not accessible experimentally. In experiments,
the EXAFS is instead calculated from data reduction using the expression [275]
χ (E) =
µexp (E)− µb (E)
∆µexp
, (3.159)
where µexp(E) is the experimentally measured absorption, ∆µexp an estimate of the
edge step, and µb(E) is a smooth background curve that is fit to the experimental
data.
µ (E) in Eq. (3.157) is proportional to the transition rate as given by Fermi’s golden
rule within the dipole approximation [220]
µ (E) ∝
∑
f
|〈ψf |εˆ · ~r|ψi〉|2 δ (E − Ef ), (3.160)
where |ψi〉 is the initial deep core state with energy Ei and |ψf〉 is the final state
with energy Ef , which is initially unoccupied. εˆ is the photon’s electric polarization
vector. In this work, the calculations of EXAFS spectra have been done using
multiple scattering approach [219, 225, 220]. In the Green’s function formulation,
µ(E) can be rewritten in terms of the imaginary part of the one-particle Green’s
function G (~r, ~r′, E) describing all of the possible ways for a photoelectron to interact
with the surrounding atoms
µ (E) ∝ −1
pi
Im 〈ψi |εˆ∗ · ~rG (~r, ~r′, E) εˆ · ~r′|ψi〉Θ (E − EF ) , (3.161)
where Θ(E − EF ) is the broadened step function at the Fermi’s energy level EF .
The Green’s function can be expanded in a multiple scattering series in which each
term contains a successive product of free propagators between geometric sites and
scattering matrices at each site. The scattering potential seen by the photoelec-
tron is approximated by the muffin-tin potential in which the atomic potentials are
approximated as spherically symmetric out to a finite radius, and the interstitial
potential between the atomic sphere is approximated as a constant.
Instead of representing χ as a function of energy, the wave vector, k =
√
2meE/~2
is used. χ (k) is then expressed as a function of the contributions from each of the
scattering paths [225, 220]
χ (k) =
∑
Γ
χΓ (k)
=
∑
Γ
S20 |FΓ (k)|
kR2Γ
sin (2kRΓ + ΦΓ (k) + 2δc (k)) e
−2σ2Γk2e−2RΓ/λ(k), (3.162)
where Γ runs over all possible multiple scattering paths Γ within a cluster of atoms.
|FΓ (k)| is the effective scattering amplitude for path Γ [220]. S20 is an amplitude
reduction factor to account for intrinsic losses and interference. RΓ is the length
of the path Γ. ΦΓ(k) is the net scattering phase shift, and δc(k) is the final-state
phase shift at the absorbing atom. σ2Γ = 〈(δRΓ)〉 is the mean square variation in
RΓ, and e
−2σ2Γk2 is the path Debye-Waller factor, which accounts for the fluctuations
of the path length due to structural and thermal disorder. λ (k) is the mean free
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path of the photoelectron and hence, e−RΓ/λ(k) accounts for the finite life-time of the
photoelectron.
The computation of EXAFS spectra using Eq. (3.162) has been implemented in the
FEFF code developed by Rehr et al. [218, 219]. First, we calculate the electronic
structure of the isolated atoms by solving the Dirac-Fock equation [Za02, Bu10]. The
atomic charge densities are then superimposed in the desired geometry, and averaged
to create the muffin-tin potential. Hedin-Lundqvist self-energy terms are added to
account for inelastic losses. Then, λ (k) is calculated from the imaginary part of
the photoelectron self-energy and the core-hole lifetime [220]. δc (k) are calculated
by integration within the atomic potential outward to the radius, and matching the
boundary conditions to free spherical waves between the atoms [220].
To calculate the set of the scattering amplitudes FΓ (k) as a function of k, a multiple
scattering expansion is done. FEFF uses the scattering matrix formalism of Rehr
and Albers [220] in which the effective scattering amplitude for each path is given
by
FΓ = TrM · FN · · · F 2F 1, (3.163)
where M is the termination matrix for the final state at the absorption site. F i is
the scattering matrix at site i. A huge number of paths enter into the calculation,
but many of them are (nearly) equivalent to each other and their calculation can be
omitted. A path filter is implemented in FEFF to estimate the importance of each
path, defined as the integral over the full k range of |χΓ (k)| dk. Any path with a
value of the integral larger than a few percent of the largest path will be used in the
calculation of χ(k).
To calculate the Debye-Waller factor as defined above, FEFF uses the correlated
Debye model [277], in which the mean-square displacement is
σ2Γ (T ) =
~
M
ωmax∫
0
dω
ω
ρΓ (ω) coth
(
β~ω
2
)
, (3.164)
where T is the temperature, M is the atomic mass, ω is the vibrational frequency,
β = 1/kBT , and ρΓ is the projected density of vibrational states. In this model, ρΓ
is given by [220]
ρΓ (ω) =
3ω2
ω2D
[
1− sin (ωRΓ/c)
ωRΓ/c
]
. (3.165)
ωD = kBθD/~ is the Debye frequency, θD is the Debye temperature, c = ωD/kD is
the Debye approximation for the speed of sound, kD = 6pi
2N/V , and N/V is the
atomic density number.
3.2.3 Circular dichroism (CD)
Circular dichroism (CD) spectra can be used to analyze the secondary structure
of proteins. As all chiral groups, protein backbone units absorb left- and right-
circularly polarized light in a different manner. Hence, the extinction coefficients of
the absorption of left- (εL) and right (εR)-circularly polarized light differ: εL 6= εR.
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The CD function ∆ε(λ) is the difference in the absorption of left- and right-circularly
polarized light, plotted as a function of the wavelength λ of the polarized light
∆ε (λ) = εL (λ)− εR (λ) . (3.166)
The integral of ∆ε(λ) over a wavelength range associated with a particular transition
from the ground state 0 to an excited state k is the rotational strength of that
transition (R0k). The latter can be calculated using the Rosenfeld equation [278]
R0k = Im
(〈
ψ0 |~µ|ψk〉 〈ψk |~m|ψ0〉) , (3.167)
where, ~µ is the electric, and ~m the magnetic transition dipole moment operator. ψ0
and ψk are the wave functions of the ground state and the excited state, respectively.
For proteins, which have a very large number of atoms and electrons, approxima-
tions are needed to calculate ψ0 and ψk. In the matrix method [279], the protein is
divided into M chromophores with a certain number of local excitations at each chro-
mophore. The approach is based on coupled-oscillator and exciton models, where
the Hamiltonian is described by energies and interactions between the transitions on
the chromophores. For protein CD spectroscopy, the most important chromophores
are the amide groups. The relevant excitations are pi → pi∗ and n → pi∗ transitions
of the amide carbonyl groups.
In the matrix method, the total wave function of the protein is expressed as a linear
superposition of basis functions Φia. Each basis function is a product of M monomer
wave functions. Electronic excitations may occur within a group but not between
groups. The basis function is further restricted to allow only one group to be excited
[206, 280, 281, 207]. Thus:
Φia = ϕ10 · · · · · ϕia · · · · · ϕM0, (3.168)
where ϕia represents the wave function of chromophores i, which has undergone an
electronic excitation ϕi0 → ϕia. The excited state wave function of the protein is
then given by
ψk =
M∑
i
ni∑
a
ckiaΦia. (3.169)
The sum above is over M chromophores and ni excitations on each chromophore.
ckia’s are expansion coefficients to be determined by solving the Schro¨dinger equation
for the excited state k of the protein [280, 281]
Hψk = Ekψk. (3.170)
The total Hamiltonian H for the protein consisting of M chromophores reads
H =
M∑
i=1
Hi +
M−1∑
i=1
M∑
j=i+1
Vij, (3.171)
where Hi is the Hamiltonian of chromophore i and Vij is the interaction potential
between chromophores.
The Hamiltonian (3.171) can be written in matrix form, in which the diagonal el-
ements are the transition energies for each transition of each chromophore, and
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the off-diagonal elements are the interaction energies between different transitions.
These interactions are the cause of the dependency of protein CD on secondary
structure.
The diagonal elements of the Hamiltonian matrix are calculated as
Hia = Eia = 〈Φia|Hi |Φia〉 . (3.172)
The off-diagonal elements of the Hamiltonian matrix are calculated as
Via,jb = 〈Φia|Vij |Φjb〉 , (3.173)
e.g. for the interaction between the transition 0 → a on chromophore i and the
transition 0→ b on chromophore j, it reads
Vi0→a;j0→b =
∫ ∫
ϕi0ϕiaVijϕj0ϕjbdτidτj. (3.174)
This interaction can be regarded as an electrostatic interaction between charge den-
sities ρ. In this case Eq. (3.174) becomes
Vi0→a;j0→b =
∫
ri
∫
rj
ρi0a (ri) ρj0b (rj)
4piε0rij
dτidτj, (3.175)
where ρi0a (ri) and ρj0b (rj) denote the transition electron densities on chromophores
i and j, respectively, ε0 is the vacuum permittivity and rij is the distance between
the chromophores.
In the “monopole-monopole” approximation, used here, the charge and transition
densities are approximated by point charges and the matrix element Vi0→a;j0→b is
re-cast as a sum of Coulomb interactions
Vi0→a;j0→b =
Ns∑
s=1
Nt∑
t=1
qsqt
rst
, (3.176)
where qs and qt are point charges on chromophores i and j. Ns and Nt are the number
of these charges on the chromophores. Thus the magnitude and the location of these
monopoles reflect the magnitude and the orientation of the transition moments.
They are critical for determining the inter-chromophore interactions.
The computation of CD spectra requires atomic coordinates and the position of the
chromophores as input. Each chromophore is parameterized by a set of monopoles,
which are superposed on the chromophoric groups in the protein, and describe their
electrostatic potential. There are commonly used parameter sets for the matrix
method: NMAabinit [207] that has been derived entirely from ab initio calculations
and NMAsemi [282] that has been derived from a combination of semiempirical
calculations and experimental data. By calculating the interaction between all the
different electronic excitations, the Hamiltonian matrix is constructed. Diagonaliza-
tion of the Hamiltonian matrix yields the energies (the eigenvalues) for all states k
and the corresponding wave functions ψk.
Rotational strengths of the transitions R0k, i.e. their spectral intensities, are cal-
culated by using Eq. (3.167). This yields a line spectrum. In an experimental
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spectrum the transitions are broadened by various mechanisms, e.g. by lifetime
broadening, vibronic coupling or interactions with the environment. Therefore, the
CD spectrum can be constructed from the rotational strengths by convoluting them
with normalized band shape functions such as a Gaussian or Lorentzian line shape
function. For Gaussian band shape functions, which typically provide better results
than Lorentzian functions, the CD spectrum reads [280]
∆ε (λ) ∝
∑
k
R0k
Γk
exp
[
−
(
λ− λk
Γk
)2]
, (3.177)
where Γk is the half-width of the Gaussian.
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Structural determinants of cisplatin
and transplatin binding to Ctr1’s
Met-rich motif: a computational
spectroscopy approach
This chapter is reproduced from Ref. [63]
Abstract
The cellular uptake of cisplatin and of other platinum-based drugs is mediated by
the high-affinity copper transporter Ctr1. The 8-residue long peptide called Mets7
(which has the amino acid sequence MTGMKGMS) mimics one of Ctr1’s extra-
cellular methionine(Met)-rich motifs. It is an excellent model for investigating the
interaction of platinum drugs with Ctr1 in in vitro and in vivo conditions. Arne-
sano et al. have shown that: (i) Cisplatin loses all of its ligands upon reaction
with Mets7 and the metal ion binds to the three Met residues and completes its
coordination shell with a fourth ligand which can be a chloride or a water/hydroxyl
oxygen. (ii) Transplatin loses only the chlorido ligands, which are replaced by Met
residues. Here, we provide information on the structural determinants of cisplatin-
Mets7 and transplatin-Mets7 adducts by computational methods. The predictions
are validated against EXAFS, NMR, and CD spectra. While EXAFS gives informa-
tion restricted to the metal coordination shell, NMR provides information extended
to residue atoms around the coordination shell and, finally, CD provides informa-
tion about the overall conformation of the peptide. This allows us to elucidate the
different reaction modes of cisplatin and transplatin towards the peptide, as well
as to propose the platinated peptides [Pt2+X]-(M*TGM*KGM*S) (X = Cl−, OH−)
and trans[Pt(NH3)2]
2+-( M*TGM*KGMS) as the most relevant species occurring in
water solution.
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4.1 Introduction
Cisplatin [cis-diamminedichloridoplatinum(II)] is one of the most widely used anti-
cancer drugs. It is active against many types of cancer, such as testicular, ovarian,
cervical, and colorectal cancers and relapsed lymphoma [87, 2]. Unfortunately, the
drug suffers from several drawbacks, such as side effects and intrinsic or acquired
resistance, which severely limit the efficacy of the drug [87, 3, 1]. The cellular
mechanisms behind the resistance of cisplatin and other platinum-based drugs are
multifactorial and not completely understood [30, 2, 3]. The generally accepted
mechanism involves an increased cisplatin detoxification, an improved repair of the
DNA lesions, and a decreased accumulation of the drug [30, 28]. Among these fac-
tors, the reduced drug accumulation is a common and distinctive feature of resistant
cells [30, 131, 2]. It is, therefore, important to characterize the molecular mecha-
nisms of cisplatin’s eﬄux and cellular uptake. The first involves the copper pumps
ATP7A and ATP7B in the secretory vesicles [153, 30, 132] and the cytosolic copper
chaperone Atox1 [110, 34]. All of these proteins can bind cisplatin and enhance its ef-
flux/sequestration [30, 132, 110, 34]. Cisplatin may be also ensnared in melanosomes
that are subsequently exported from the cells [177]. The cellular uptake is governed,
at least in part, by the homotrimeric copper transporter Ctr1 [30, 178, 110]. Ctr1
forms a channel-like pore in the membrane [179], featuring intra- and extracellular
domains. Flow of the active platinum substrate through the channel-like pore of
the Ctr1 trimer has been proposed [180, 181]. Alternatively, cisplatin could form
coordination bonds with the protein [142, 143]. The extracellular N-terminal domain
contains methionine(Met)-rich motifs, which are able to bind copper [182]. Met’s
sulfur is indeed a good donor atom for platinum [183]. Hence, some cisplatin could
bind to the extracelular Met-rich motifs of Ctr1 and an endocytic vesicle might be
formed. In this way the vescicle could incorporate cisplatin present in the extra-
cellular solution while protecting the drug from deactivation and transporting it to
subcellular compartments [142, 143].
To provide insights on Ctr1–cisplatin interactions, Arnesano et al. have carried
out in vitro studies on reactions of cisplatin, the inactive isomer transplatin [trans-
diamminedichloridoplatinum(II)], and other platinum complexes with the MTGMKGMS
peptide (Mets7) [142, 143]. The peptide mimics the seventh Met-rich motif of yeast
Ctr1. Circular dichroism (CD) measurements showed that Mets7 features a β-turn
conformation after reacting with cisplatin, whilst it is a random coil in the Apo form
[142]. Furthermore, electrospray mass spectrometry (ESI-MS) data showed that cis-
platin progressively loses all ammine and chlorido ligands and ultimately coordinates
only to Mets7. This contrasts with transplatin, which keeps the two ammine lig-
ands. Consistently, 1H and 13C nuclei of -CH3 and γ-CH2 of methionines feature
a large downfield shift in NMR spectra upon platinum coordination [142]. Other
groups also reported a similar binding mode of cisplatin to partial or full-length
N-terminal domain of human Ctr1 [146, 147]. Hence, Mets7 is a good mimic of the
whole N-terminal domain of Ctr1 in terms of reactivity against cisplatin.
The structural basis of cisplatin and transplatin binding to Mets7 is still lacking.
Herein, we have addressed this issue by using computational tools. Computational
approaches are indeed widely used to investigate cisplatin and its interactions with
biomolecules [45]–[62], [155]–[165]. Specifically, we have used hybrid Car-Parrinello
density functional theory-based QM/MM simulations [166, 167, 168, 169, 170, 171,
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172] on models of platinated Mets7, extracted from available experimental informa-
tion [142, 143]. These models contain the platinum moieties ([PtCl]+, [Pt(H2O)]
2+,
[Pt(OH)]+ and trans-[Pt(NH3)2]
2+). The QM/MM simulations, albeit rather accu-
rate, can cover only rather short time scales (0.1 ns or less). Whilst these are likely to
be enough to provide valuable information on the local platinum coordination, global
conformational properties of the peptide are out of reach. To extend the time-scale of
the simulations, we have developed AMBER-type [173] force field parameters of the
platinum moieties based on the QM/MM simulations via the so-called “force match-
ing” procedure [174]. The parameters are derived so as to reproduce the QM/MM
forces, the electrostatic potential, and the electric field obtained by QM/MM sim-
ulations. This procedure was already applied successfully to platinated DNA [175].
Finally, 0.2µs-long replica exchange simulations [176] based on these force field pa-
rameters are performed for the platinated peptides. The accuracy of the predicted
models is established by a comparison with the NMR and CD data already reported
in the literature [142, 143], as well as EXAFS spectra measured expressly for this
study.
4.2 Computational protocol
4.2.1 Molecular models
We have considered in total seven models: one free Mets7 peptide (called Apo here-
after), three cisplatn-Mets7 (C1–C3) and three transplatin-Mets7 (T1–T3) adducts
(Fig. 4.1).
The cisplatn-Mets7 adducts include [Pt2+X]-(M*TGM*KGM*S), in which X = Cl−
(C1); H2O (C2); OH
− (C3).
The transplatin-Mets7 adducts are trans-[Pt(NH3)2]
2+-( M*TGM*KGMS) (T1); trans-
[Pt(NH3)2]
2+-( M*TGMKGM*S) (T2); trans-[Pt(NH3)2]
2+-(MTGM*KGM*S) (T3)
(“*” indicates the donated methionine).
Apo was built as a linear chain by using the Leap package [185].
In the cisplatin-Mets7 adducts (C1–C3, Fig. 4.1), the platinum coordination was
taken from DFT-based optimized model compounds (see Appendix A.1). The plat-
inum coordination’s donor atoms are the Mets7’s three methionine sulfurs and either
a chloride (C1), or a water oxygen (C2), or a hydroxyl oxygen (C3).
In the transplatin-Mets7 adducts (T1–T3, Fig. 4.1), the donor atoms are two am-
mine nitrogens and two sulfur atoms of either Met1 and Met4 (T1), or Met1 and
Met7 (T2), or Met4 and Met7 (T3). The six systems, along with Apo, were inserted
in boxes containing water molecules and chloride counterions (Tab 4.1).
The platinated (C1–C3, T1–T3) and Apo peptides were subjected to 0.4 µs of
preparatory AMBER-based molecular dynamics (MD) simulations using the NAMD
program [186]. The AMBER parm99 force field [173] with the ”Stony Brook” mod-
ification for the backbone torsions [190], the TIP3P water model [192] and the
Smith&Dang force field [193] were used for the peptide, water molecules, and coun-
terions, respectively. The bond distances and angles were constrained using the
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Figure 4.1 Structural models of platinated and Apo peptides emerging from REST
and QM/MM simulations. The backbone conformations of the last
QM/MM snapshot (in red ribbons) and a representative REST snap-
shot (in blue ribbons) are superimposed. The QM atoms are shown in
stick-and-balls (CB=Cβ, CG=Cγ, CE=C). Water is shown in lines.
Counterions are not shown for the sake of clarity.
SHAKE algorithm [235] to the values taken from [Pt(SH2)3Cl]
+, [Pt(SH2)3(H2O)]
2+,
[Pt(SH2)3(OH)]
+ and trans-[Pt(SH2)2(NH3)2]
2+ gas-phase-optimized structures (Tab.
A.1 in Appendix). Long-range electrostatic interactions were evaluated using the
Particle Mesh Ewald (PME) method [236] The cutoff for the real part of the PME
and for the van der Waals interaction was set to 10 A˚. An integration time step of
2fs was used. Constant temperature (300 K) and pressure (1 atm) conditions were
achieved by using Langevin dynamics with a coupling coefficient of 5 ps and the
Nose-Hoover Langevin piston algorithm [237] with an oscillation period of 200 fs
and the damping timescale of 100 fs. A cluster analysis [187] allowed us to identify
representative structures of the most populated clusters. It turned out that only one
cluster was sufficient to comprise 70% or more of the conformational space explored
by the MD trajectories. Hence, we considered only the representatives of the most
populated clusters.
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Table 4.1 Selected features of the simulated models
4.2.2 QM/MM simulations
The six representative structures of C1–C3 and T1–T3 underwent hybrid Car-
Parrinello QM/MM simulations [167, 168, 169, 170, 171]. We used the CPMD
program [188] combined with the classical MD GROMOS96 code [189], through
the interface developed by Rothlisberger et al. [168, 169]. The MM regions com-
prised the peptide frame, the solvent, and the counterions (Fig. 4.1). These were
described with the AMBER parm99SB force field [173] with the “Stony Brook”
modification for the backbone torsions [190], the TIP3P model for the solvent [192]
and the Smith&Dang force field for the counterions [193]. The QM part concerns
the platinum coordination polyhedron (Fig. 4.1) and was treated by density func-
tional theory (DFT), with the BLYP recipe for the exchange-correlation functional
[195, 196]. The wavefunction was expanded in a plane-wave basis set up to an
energy cutoff of 70 Ry. Only the valence electrons were treated explicitly (in the
case of Pt, electrons in the n=5 shell are also included in the valence). The core
electrons were described using norm-conserving pseudopotentials of the Martins-
Troullier type [197]. Isolated system conditions were applied [198]. The β carbon
(CB) atoms linked to the MM part by covalent bonds were saturated by “capping”
hydrogen atoms[170]. The electrostatic interactions between QM and MM atoms
were calculated using a fully Hamiltonian hierarchical scheme [169]. In particular,
the short range electrostatic interactions between QM and MM part were taken
explicitly into account within a radius of 5.3 A˚ around every QM atom using an
appropriate modified Coulomb potential to prevent electron spill-out [169]. Beyond
this first shell and within 10.6 A˚, the electrostatic interactions are calculated using
the D-RESP charge scheme [168]. In the outermost region, a multipole expansion
scheme is used [168]. A time step of 0.097 fs was used. A fictitious electronic mass
of 400 a.u. for the Car-Parrinello dynamics was employed. Constant temperature
conditions were achieved using the Nose-Hoover chain thermostat[199, 200, 201].
Nonbonded interactions were evaluated as in the previous MD simulations. 2000
steps of simulated annealing were performed to relax the representative snapshots of
the previous MD simulations. Then, the systems were slowly heated up to 300 K by
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gradually increasing the target temperature (30 K after every 1000 steps). Finally,
25 ps-long QM/MM simulations were carried out.
4.2.3 Force matching procedure
AMBER-type force field parameters of the QM regions were obtained by applying
the force matching procedure of Refs. [174, 175] and described in section 3.1.6 to
300 QM/MM conformations, selected at every 0.08 ps. The atomic partial charges
(Tables. A.2–A.3 in Appendix) were obtained through a fit to the electrostatic
potential and the electric field. These, along with van der Waals parameters taken
from AMBER parm99SB force field [173, 190], were subtracted from the total forces
acting on the QM atoms to yield the bonded forces. A least-squares fit of the
latter allowed to obtain the AMBER-type bond, angle, and dihedral angle force
field parameters (Tables. A.4–A.6 in Appendix). Equilibrium bond lengths and
bond angles were taken from the QM/MM averaged values. The parameters for
Met, water, and OH turned out to differ only by 30 to 40% relative to the original
AMBER parameters.
4.2.4 Replica exchange with solute tempering (REST) simula-
tions
Apo, C1–C3, and T1–T3 underwent, respectively, 0.5, 0.2, and 0.2 µs replica ex-
change with solute tempering (REST) simulations [176] in the NPT ensemble (see
Sec. 3.1.9, for more details). The initial structures of the platinated peptides were
the last QM/MM snapshots, whilst for Apo, the initial linear structure inserted in
water was used. Eight replicas covered a temperature range from 300 K to 600 K
for each system (Fig. 4.2). The force field was the same as that of the previous MD
simulations, except that the platinated moieties were described by the parameters
obtained via the force matching procedure.
First, each replica was prepared independently by 5-ns-long MD simulations, then
the REST simulations were performed with the replica exchange being attempted
after every 5 ps. The acceptance ratios were between 15 and 25%. The integration
step of 2 fs was used. In each replica, the temperature was controlled by Nose-
Hoover chain thermostat [199, 200, 201], whereas the pressure was controlled by
Parrinello-Rahman barostat [202]. The REST simulations were carried out with the
Gromacs 4.5.3 program [203]. The DSSP approach [204, 205] was used to assign the
secondary structures to the conformations along each of the REST trajectories. The
percentage of each secondary structure type was then estimated from the frequency
of its occurrence during the REST simulations.
Next, 25 ps-long QM/MM simulations were carried out for Apo starting from the
representative structures obtained from REST simulation. The QM part of the Apo
model includes 3 Met residues (Fig. 4.1). The MM part consists of the peptide
frame, the solvent, and the counterions. Exactly the same procedure as the one
carried out for the platinated peptides (see Sec. 4.2.2) was employed. Finally, the
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Figure 4.2 Potential energy distribution of 8 replicas (in different colors) simulated
with REST method for the platinated peptides C1-C3 and T1-T3 and
the apopeptide.
last snapshots of the REST trajectories of Apo, C1–C3 and T1–T3 underwent 25-
ps-long QM/MM simulations with the same QM/MM procedure described in Sec.
4.2.2.
4.2.5 Computational spectroscopy
NMR chemical shifts and EXAFS spectra were evaluated based on the QM/MM tra-
jectories of Apo and the platinated peptides before and after the REST simulation.
The CD spectra were calculated from the REST trajectories.
4.2.5.1 CD
The CD spectra were averaged values over 500 equidistant snapshots along the 200-
ns-long REST trajectories. The web interface DichroCalc [206, 207], which imple-
ments the theoretical approach described in Sec. 3.2.3, was used. The CD spectra
turned out not to change with increasing REST simulation time (Fig. 4.3), suggest-
ing that these calculated properties are well converged during the simulations.
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Figure 4.3 Running averages of CD spectra calculated from the REST trajectories
for cisplatn-Mets7 (C1-C3) and transplatin-Mets7 (T1-T3).
4.2.5.2 NMR
1H, 13C, and 195Pt NMR shielding constants were calculated as averages over the
50 equidistant QM/MM snapshots. For the first two nuclei (1H and 13C), we used
the approach in Refs. [208] and [209] for the QM parts of C1–C3, T1–T3, and
Apo. Because the QM/MM boundary cuts through the CA-CB bonds, the CB and
HB atoms are very close to the MM part. They are expected to be overpolarized
by the nearby MM charges. Hence, the calculation of shielding constants was not
carried out for them. The shielding constants were converted to the NMR chemical
shifts using the shielding constant of tetramethylsilane (TMS). See Appendix A.2
for details on conversion of the shielding constant to the chemical shifts.
For 195Pt NMR shielding constants we used the ADF code [211, 212, 213] on the QM
parts of C1–C3 and of T1–T3. The quadruple-quadruply polarized basis set (QZ4P)
for the Pt and the triple-singly polarized basis set (TZP) for the other atoms were
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used. The calculations were carried out at the DFT-PBE level [214]. This choice
of basis sets and functional was shown to give reliable results for the calculation of
195Pt chemical shifts [215]. Scalar relativistic effects were taken into account with the
zero order regular approximation (ZORA) approach [216, 217]. The MM atoms were
included as point charges. The chemical shift was referenced to that of [PtCl6]
2− in
water at room temperature, as obtained by an additional QM/MM simulation (see
Appendix A.3).
4.2.5.3 EXAFS
The EXAFS spectra were calculated at the Pt edge. The FEFF6L code [218, 219,
220] was applied over 500 equidistant QM/MM snapshots (See Sec. 3.2.2 for the
theoretical approach). The FEFF calculation of EXAFS spectra are cheaper than
that of NMR chemical shifts. Therefore, a larger number of QM/MM snapshots were
used for EXAFS calculations. For each snapshot, a cluster of atoms within 5 A˚ from
the platinum atom was extracted, taking into account the periodic boundary condi-
tions, and input into the FEFF6L program to generate the EXAFS spectrum. The
k3-weighted EXAFS spectra were Fourier-transformed using the IFEFFIT program
[221] to obtain the real-space representation.
4.3 EXAFS measurements
EXAFS measurements were done by Arnesano, F.; Scintilla, S. and Natile, G. [63].
The samples were prepared as follows. 3.0 mM aqueous solutions of Apo containing
100 mM NaCl, were treated with one mol equivalent of either cisplatin or transplatin
and the mixtures were kept for 24 h at 310 K before recording the XAS spectra. The
adduct formation between Mets7 and the selected platinum complex was checked by
ESI-MS as previously described [142]. The samples were loaded in Teflon cells with
Kapton windows, mounted in a two-stage Displex cryostat, and kept at 20 K during
the data collection. XAS spectra were recorded at beamline D2 of the European
Molecular Biology Laboratory (EMBL) outstation at Deutsches Elektronen Syn-
chrotron (DESY, Hamburg, Germany). The DORIS storage ring operated at 4.5
GeV with the positron beam current ranging from 150 to 95 mA. Ionization cham-
bers in front and behind the sample were used to monitor the beam intensity. A
Si(111) double-crystal monochromator scanned X-ray energies around the platinum
L3-edge (11564 eV). The X-ray absorption spectra were recorded as platinum L3 flu-
orescence spectra with a Canberra 13-element germanium solid-state detector. For
both samples, 10 scans were collected and averaged to ensure comparable statistics.
Data reduction, such as background removal, normalization, and extraction of the
fine structure, was performed with KEMP [222]. The extracted platinum L3-edge
extended X-ray absorption fine structure (EXAFS) data were converted to photo-
electron wave vector k-space and weighted by k3. The full, k3 weighted, EXAFS
spectra (30-1000 eV above E0) and their Fourier transforms (FT) calculated over
the range 2.0-16.0 A˚−1 were compared with theoretical simulations.
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Table 4.2 The averaged RMSD of the REST structures with respect to the corre-
sponding last QM/MM structures.
4.4 Results and discussion
In the cisplatin-Mets7 adducts (C1–C3, Fig. 4.1), the three methionine sulfurs act
as donor atom to the Pt(II) ion, while the remaining fourth position may be oc-
cupied by chloride (C1), or water molecule (C2), or hydroxyl group (C3). In the
transplatin-Mets7 adducts (T1–T3), the two ammine ligands remain bound to Pt in
trans arrangement. The other two ligands come from the two methionine sulfurs of
either Met1,4 (T1), Met1,7 (T2) or Met4,7 (T3). We used QM/MM simulations and
replica exchange with solute tempering (REST) method to investigate the Pt(II) ion
coordination and the conformational properties of these platinated peptides, along
with the conformational feature of the unbound peptide (Apo, Fig. 4.1). The direct
comparison between the calculated and experimental spectroscopic data (EXAFS
from this work, along with NMR and CD from Ref. [142]) established the accuracy
of our structural predictions.
4.4.1 Peptide conformation
During the QM/MM simulations, the peptides’ conformations do not change sig-
nificantly (RMSD between the first and the last snapshot < 0.6 A˚). In addition,
the structures obtained from REST simulations are not too dissimilar to those from
QM/MM simulations (Fig. 4.1): The averaged RMSD of REST structures with
respect to the last QM/MM snapshots ranges from 1.1 to 2.2 A˚ (Tab. 4.2). The
C1–C3 models are less flexible than the T1–T3 ones, as indicated by an analysis of
the RMSF values. These are less than 1 A˚ for the first and between 1.1 and 1.5 A˚
for the latter (Tab. 4.3).
The content of the secondary structure (ss) during the REST simulations is given
in Tab. 4.4. In the case of cisplatin-Mets7 adducts, C2 and C3 contain more β-turn
(>47%) than coil (<38%). In contrast, C1 contains more coil (50%) than β-turn
(30%), and a small content of α-helix (8%). In the case of transplatin-Mets7, T1
contains mostly coil (59%) and only 26% of β-turn. Instead, both T2 and T3 have
more β-turn than coil. Bends are found in all cases with rather small content (<
16%). In the models with large β-turn contents, the latter is more likely to be found
between the platinated methionines. The large content of turn appears to correlate
with the emerging β-turn-type band in the calculated CD spectrum (Fig. 4.4).
The calculated CD spectrum of C3 is in good agreement with the experimental one
(Fig. 4.4). It has a positive peak at 200 nm, which features the β-turn conformation
[223]. The CD spectrum of C2 model has a similar shape but its intensity is slightly
larger than that of the experimental spectrum. In contrast, in the spectrum of C1,
the positive peak is shifted towards a lower wavelength ( 190 nm) compared to the
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Table 4.3 The root mean square fluctuations (RMSF), which is defined as the
standard deviation of the backbone RMSD. The smaller the value of
RMSF, the more rigid the conformation, and vice versa.
Table 4.4 DSSP secondary structure assignment for the ensembles of conforma-
tions generated by REST simulations.
experimental peak. In addition, it features a weak negative band at 210 nm. Hence,
C2 and C3 reproduce better the β-turn feature of the experimental CD spectrum
than C1. Since the only difference between C2 and C3 is the state of deprotonation
of the coordinated solvent molecule (Fig. 4.1), an equilibrium between the two
species may be present. The calculated CD spectrum of T1 reproduces fairly well
the experimental one (Fig. 4.4). Those of T2 and T3 have a very large positive
band at about 200 nm, which features their β-turn conformation. This contrasts
with the experimental observation that the binding of transplatin to Mets7 only
slightly modifies the random coil structure of the free peptide [142]. This might
imply that only T1 gives an important contribution to the total CD spectrum of the
transplatin-Mets7 adduct, while T2 and T3 are almost irrelevant.
The calculated CD spectrum of Apo has a positive band at 195 nm and a negative
band at ∼210nm, which suggest some content of beta sheet structure. However,
the experimental spectrum is characteristic of a random coil conformation [142].
The reason behind the discrepancy between experiment and theory might be due
to sampling issues and to limitation of the force field. In particular, simulations
based on the AMBER force field[173, 190], which has been used here, might bias
random coiled structures towards the formation of secondary structure elements
[226, 227, 228, 229]. In this respect, we stress here that the main focus of the paper
is to reproduce the structural determinants of the platinated peptides, for which our
computational procedure appears to be relatively accurate.
4.4.2 Platinum coordination
In the QM/MM simulations, the Pt geometry deviates only slightly from the ideal
square-planar geometry, e.g. the difference from a square angle is less than 10%
(Tab. 4.5). The Pt-S bond lengths range from 2.3 to 2.4 A˚ (Tab. 4.5). These
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Figure 4.4 Calculated and experimentally measured [142] CD spectra of cisplatin-
Mets7 (a) and transplatin-Mets7 (b) adducts.
values are very similar to those of corresponding model compounds ([Pt(SH2)3Cl]
+,
[Pt(SH2)3H2O]
2+, [Pt(SH2)3OH]
+ and trans-[Pt(SH2)2(NH3)2]
2+) optimized in the
gas phase (Tab. A.1 in Appendix). Oxygen atoms from water molecules and/or the
peptide terminus occupy the axial positions of the platinum complex, at a distance
from the metal ranging from 2.6 to 2.8 A˚ (Fig. 4.5). In the REST simulations,
the bond lengths and angles are very similar to those of QM/MM simulations (Tab.
4.5).
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Figure 4.5 Pt-O radial pair distribution functions calculated from the QM/MM
trajectories. Left: cisplatin-Mets7, right: transplatin-Mets7.
From the QM/MM calculations, local spectral properties can also be obtained. De-
spite the short time scale, the QM/MM calculations can provide rather accurate
spectroscopic properties of the Pt site. This is because the overall conformations of
the peptides, and in particular of the Pt site, in the QM/MM simulations are not
too dissimilar to those obtained by the subsequent sampling-enhanced REST simu-
lations. Furthermore, the QM region is relatively well sampled within the QM/MM
time scale (see Sec. Appendix A.4). Here, we present EXAFS and NMR results
from QM/MM simulations. The results of NMR obtained from QM/MM simula-
tions after the REST simulations are reported here, whereas these berfore the REST
simulations are reported in the Appendix.
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Table 4.5 Structural parameters calculated from QM/MM and REST simulations
for cisplatin-Mets7 (C1-C3) and transplatin-Mets7 (T1-T3) adducts.
Standard deviations are shown in parentheses. Bond lengths are in
angstrom and angles in degree.
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4.4.2.1 EXAFS spectra
The calculated k3-weighted EXAFS spectra at the Pt edge of C1–C3 and T1–T3
reproduce well the experimental data (Fig 4.6 a-b). Also the corresponding Fourier
transforms (FT’s) of the calculated EXAFS spectra are in fair agreement with those
of the experiments (Fig. 4.6 c-d).
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Figure 4.6 Calculated and experimental EXAFS spectra at the Pt edge of
cisplatin-Mets7 (a) and transplatin-Mets7 (b) adducts. The experi-
mental spectrum has been measured in this work. Fourier Transforms
of the spectra in (a) and (b) are given in (c) and (d), respectively. They
are plotted as a function of the scattering path length of the photoelec-
tron R. Note that R does not correspond to a real interatomic distance
since the peak positions are shifted inward, with respect to the bond
distances; due to the phase shifts of the photoelectron (i.e. increase in
its kinetic energy caused by the electronic potentials of both the scat-
tering and the absorbing atoms) [225]. The shift, therefore, depends
on both the absorbing and scattering atom types, and in our cases is
approximately 0.4 A˚ (Tab. 4.5.
The FEFF approach of EXAFS calculation is based on the multiple-scattering the-
ory, in which the total EXAFS are the sum over all possible scattering paths of the
photoelectron [220]. It is, therefore, possible to separate contributions due to each
type of ligand’s atoms and to assign peaks of EXFAS to the corresponding atoms.
In Fig. 4.7, EXAFS is calculated separately for each type of donor atoms in order
to distinguish between peaks due to different atoms.
For the cisplatin-Mets7 adducts (Fig. 4.6 c) the three FT’s feature a large peak,
mainly caused by the back-scattering from the three Pt-bound sulfur atoms and a
chloride (C1) or a water oxygen (C2); a small side peak on the left which appears
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clearly only in C3 is due to the hydroxyl oxygen (Fig. 4.6 c). Oxygen atoms at
the axial position are found to give small contribution to the EXAFS signals of
all models. The main contributions from each type of ligand’s atoms to the total
EXAFS spectra are shown in (Fig. 4.7). The peak heights of C2 and C3 are lower
than the experimental one. On the contrary, the peak height of C1 is greater. We
note that the EXAFS spectra were taken at high chloride concentration (100 mM,
see Methods), while the CD spectra were taken at low chloride concentration [142].
Therefore model C1, which did not appear to give significant contribution to the CD
spectrum, could give a significant contribution to the EXAFS spectrum.
For the transplatin-Mets7 adducts (Fig. 4.6 d), the FT’s feature two large distinct
peaks in the first coordination shell. The first peak is due to the ammine nitrogen
atoms and the second peak is due to the Met sulfur atoms (Fig. 4.7). The large
difference in length between Pt-S and Pt-N bonds (Tab. 4.5) causes such a splitting.
Again, oxygen atoms at the axial position are found to give small contribution to
the EXAFS signals of all models The magnitude of FT’s of T1–T3 is slightly smaller
than those obtained by experiment.
4.4.2.2 NMR chemical shifts
The calculated 13C and 1H NMR chemical shifts of the platinated and Apo peptides
reproduce the experimental values within the indicated standard deviations (Tab.
4.6). In particular, as observed for the experimental data, the values of 1H and 13C
chemical shifts at the γ-CH2 and -CH3 residues of the platinated peptides (C1–C3
and T1–T3) are larger than those of the Apo (Tab. 4.6). This is consistent with the
experimental observation that the binding of cisplatin and transplatin to the Mets7
peptide causes a large downfield shift in the NMR signals for the γ-CH2 and CH3
atoms of all three methionines [142]. The downfield shift of γ-CH2 and -CH3 atoms
of all three methionines, also in the case of the transplatin-Mets7 adducts where
only two methionines are coordinated to platinum, indicates that the three models
are in fast exchange even if they can contribute differently to the overall spectrum.
The calculated 195Pt chemical shifts of C1 and C3 reproduce quite well the exper-
imental data (Tab. 4.7). That of C2 deviates significantly from the experimental
value. This might imply that the C2 model is less relevant than C1 and C3. As
already pointed out in the discussion of the EXAFS spectra, also the NMR spectra
were taken at a rather high chloride concentration (3.0 mM). Under these conditions
model C1 could gain relevance and contribute to the overall NMR spectra. The 195Pt
NMR chemical shifts of T1–T3 do not differ very much. The difference between
cisplatin-Mets7 and transplatin-Mets7 (∼1000 ppm) is fairly well reproduced by our
calculations.
The use of the REST trajectories for calculating the CD spectra, whereas the
QM/MM trajectories have been used to calculate the NMR and EXAFS spectra,
deserve an additional comment. The CD spectrum is obviously sensitive to the
global conformations of the peptides’ backbone. Therefore, we used for its calcula-
tion a sampling-enhanced technique, such as REST [176], that samples extensively
the conformational space. On the other hand, the NMR chemical shifts of the Pt
ligands and the EXAFS spectra at the Pt edge are expected to be sensitive to the
local geometry (bond lengths and bond angles) of the plati-num coordination shell.
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Table 4.6 13C (top) and 1H (bottom) NMR chemical shifts (in ppm) of the Pt-
coordinated Met residues of cisplatin-Mets7 (C1–C3) and transplatin-
Mets7 (T1–T3) adducts after REST simulations. The corresponding
values before REST are reported in Tables. A.8–A.10 in Appendix.
Standard deviations are shown in parentheses. See Fig. 4.1 for atom
name conventions.
Table 4.7 195Pt NMR chemical shifts (in ppm) of the cisplatin-Mets7 (C1–C3) and
transplatin-Mets7 (T1–T3) adducts after REST simulations. The cor-
responding values before REST are reported in Tab. A.11 in Appendix.
Standard deviations are shown in parentheses.
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QM/MM describes accurately the metal ion coordination polyhedra in metal-based
biomolecules [170]. Therefore, we can expect accurate results based on the QM/MM
trajectories. However, in this case sampling is obviously much more limited than
in the case of the REST simulations. To address this issue, we compare the results
from two sets of QM/MM calculations, before (Tables A.8–A.11, in Appendix) and
after (Tables 4.6–4.7) the REST simulations. It turns out that the results are essen-
tially the same, in spite of the fact that the conformations of the peptide frame at
the end of the REST trajectories are rather different from those at the beginning.
Based on these findings, we suggest that the EXAFS and NMR shifts do not depend
significantly on the peptides’ global conformations but rather they depend on the
local environment. This feature has been found also in several other bioinorganic
systems [230, 231, 232].
4.5 Conclusions
The cellular uptake of cisplatin is mediated by the high-affinity copper transporter
Ctr1 [30, 178]. The 8-residue long peptide (Mets7) is able to mimic the extracel-
lular Met-rich N-terminal motifs of yeast Ctr1 [29]. The reaction of cisplatin and
transplatin with Mets7 was characterized experimentally by Arnesano F. et al. [29].
Here, the structural and spectroscopic properties of cisplatin and transplatin adducts
with Mets7 (models C1–C3 and T1–T3, respectively, see Fig. 4.1) have been investi-
gated, for the first time, by hybrid Car-Parrinello QM/MM simulations. Information
about the overall conformation of the peptide could be deduced from CD spectra.
To this end, 200 ns-long REST simulations were carried out for the adduct models.
The simulations were based on the force field parameters obtained by force match-
ing procedure [174] for the platinated moieties. The configurationally averaged CD
spectra were calculated for each of the models.
It turns out that the CD spectra of different simulated species show rather differ-
ent patterns. As for the CD spectrum of the cisplatin-Met7 adduct, we notice that
the band wavelengths of the spectra of C2 and C3 models, characteristic of a β-
turn structure, is in a good accord with the experimental one. The spectrum of C3
matches the intensity of the experimental one better than that of C2. In contrast,
the C1 model shows much worse correspondence, particularly in terms of band wave-
lengths. We conclude that (i) the spectrum of the C3 model, in which the ligands of
the Pt(II) ion are three Met residues and a hydroxyl group, gives the most important
contribution to the total CD. In addition (ii), in the experimental conditions of Ref.
[29], the coordinated water molecule is deprotonated so as to reduce the net positive
charge of the complex. In the case of the transplatin-Mets7 CD spectrum, the band
intensities and wavelengths of the T1 model show good agreement with the experi-
mental ones. Those of the T2 and T3 models are instead significantly different from
the experimental ones and show a strong signal characteristic of a β-turn structure.
We conclude that the T1 model (coordination to platinum of Met1 and Met4, Fig.
4.1) is likely to give a much greater contribution to the total CD than those of the
other two models.
Concerning the Pt coordination, since experimental data for the bond lengths and
angles are not available, the consistency between the Pt-coordination geometry of
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the simulated models and the real ones has been checked by comparing the calculated
Pt EXAFS spectra of C1–C3 and T1–T3 with the experimental ones reported here
for the first time. The calculated EXAFS spectra of the three models show good
agreement with the experimental spectra. Differently from the CD spectra, the
EXAFS spectra were taken at considerably higher chloride concentration. Hence,
model C1 (chloro species), which did not contribute appreciably to the CD spectra,
can instead give a significant contribution to the EXAFS spectra. Calculations show
that, indeed, this is the case.
The calculated 1H and 13C NMR chemical shifts are in rather good agreement with
the experimental chemical shifts. The differences in the calculated 1H and 13C NMR
chemical shifts between Apo and platinated peptides confirm that platinum binding
causes a downfield shift of the NMR signals belonging to the Met residues that
are bound to platinum as observed experimentally. The calculations also confirm a
contribution of models T2 and T3 to the overall spectra to account for the downfield
shift observed for γ-CH2 and -CH3 of all methionines of Mets7. The calculated
195Pt chemical shifts also show that model C1 can give a relevant contribution to
the experimental spectrum taken at a rather high chloride concentration. In contrast,
model C2, whose computed spectrum significantly deviates from the experimental
one, contributes much less.
The calculated 1H and 13C NMR chemical shifts are in rather good agreement with
the experimental chemical shifts. The differences in the calculated 1H and 13C NMR
chemical shifts between Apo and platinated peptides confirm that platinum binding
causes a downfield shift of the NMR signals belonging to the Met residues that
are bound to platinum as observed experimentally. The calculations also confirm a
contribution of models T2 and T3 to the overall spectra to account for the downfield
shift observed for γ-CH2 and -CH3 of all methionines of Mets7. The calculated
195Pt chemical shifts also show that model C1 can give a relevant contribution to
the experimental spectrum taken at a rather high chloride concentration. In contrast,
model C2, whose computed spectrum significantly deviates from the experimental
one, contributes much less.
Different spectroscopies, combined with quantum chemical calculations, provide
valuable complementary insights in bioinorganic systems [233]. Here, we have cal-
culated a variety of spectroscopic data (CD, EXAFS, and NMR), which are readily
compared with experiments. The exhaustive comparison of the calculated spectro-
scopic data with the experimental ones has been proved useful. It allows us to make
structural prediction of platinated Mets7 species in aqueous solution.
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Figure 4.7 Contributions from different types of scattering atoms to the total EX-
AFS spectra, calculated from the QM/MM trajectories.
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5
Binding of the platinated DNA to
HMGB1 protein: preliminary results
5.1 Introduction
DNA is the primary target of cisplatin [1, 2, 4]. It binds preferentially to two adjacent
guanine bases within a strand of DNA [1, 2, 4]. Cisplatin binding causes damages in
DNA (cisplatin-DNA adducts) which, in turn, inhibit DNA replication [21, 22] and
transcription [24, 25]. The inhibition of these vitally important cellular processes
leads to apoptotic death of tumor cells.
Cisplatin-DNA adducts are recognized by many DNA-binding proteins [1, 3]. The
most characterized among these proteins is the High Mobility Group Box 1 protein
(HMGB1) [1, 24, 76, 78]. Interestingly, HMGB1 has been found to inhibit Nucleotide
Excision Repair (NER) of cisplatin-damaged DNA by binding to cisplatin-DNA
adducts and shielding them from being repaired by NER proteins [72, 73, 74, 78]
(see Sec. 2.2.2 for more details).
X-ray studies of cisplatin-d(CCUCTCTG*G*ACCTTCC)-d(GGAGAGACCTGGAAGG)
in complex with the HMGB1 domain A (G* is the platinated base) have shown
the molecular 3-D structure of the cisplatin-DNA-HMGB1 complex (Fig. 5.2) [76].
HMGB1 consists of two DNA-binding domains (A and B), each containing three
alpha helices forming an L-shape structure that facilitates DNA binding [77] (Fig.
5.1). The concave surfaces of HMGB1 domain A form hydrogen bonds as well as
hydrophobic and water-bridging contacts with the minor groove of cisplatin-DNA
adduct. The binding affinity of HMGB1 to cisplatin-DNA adduct at is high Kd
1 =
0.7 ± 0.1 nM [78].
1Kd is given by
Kd =
[P][D]
[P ·D] , (5.1)
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HMGB1 
DNA 
Pt 
Figure 5.1 The X-ray structure of cisplatin-DNA-HMGB1. The DNA is shown
with bond representation, HMGB1 with Connolly surface representa-
tion and cisplatin moiety in van der Waals balls. Hydrogen atoms
missing in the X-ray structure were added using the Leap program
[185].
Molecular recognition of cisplatin-DNA adducts by HMGB1 protein is a key cellular
event in inducing the antitumor effect of cisplatin [1, 3]. Therefore, determining the
molecular mechanism of HMGB1 binding to cisplatin-DNA adduct would be a next
fundamental step towards better understanding of the molecular basis of action as
well as resistance mechanism of cisplatin.
The free energy as a function of the collective variables (CVs) describing the associ-
ation process of HMGB1 and the platinated DNA is a key physical quantity of the
binding process. Metadynamics method and its variants have emerged as a powerful
technique to calculate such quantity [284, 285] (see Appendix A.5). It is based on
a dimensional reduction and on a suitable history-dependent potential. First, it re-
where [P], [D] and [P·D] are concentrations of protein, DNA and protein-DNA complex, respec-
tively. Since Kd is an equilibrium constant, it is related to the Gibbs free energy difference ∆G via
Kd ∝ exp
[
− ∆G
kBT
]
, (5.2)
where kB is the Boltzmann constant and T is the temperature.
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quires identifying a set of CVs, which can properly describe the activated process of
interest. The dynamics in the space of CVs is biased by a time-dependent potential,
defined as a sum of Gaussians centered along the trajectory followed by the CVs
[284]. This potential in time fills minima in the free energy surface. At the end, sum
of the Gaussians provides the negative value of the free energy [284]. Metadynamics,
as a variety of other free energy methods including thermodynamic integration and
umbrella sampling, forces the biomolecules to explore their conformational space
quite rapidly. This issue depends crucially on the choice of CVs, which must pro-
vide a satisfactory description of the reaction coordinates of the process we wish to
investigate. If an important CV is not included, then the simulation will suffer from
serious artifacts [284, 285]. This problem might be overcome by combining well-
tempered metadynamics (a variant of metadynamics) with parallel tempering (PT)
[286, 287, 288]. The strengths of both approaches are combined: Well-tempered
metadynamics ensures the convergence of the free energy profile to a correct value,
whereas PT exploits temperature to accelerate the sampling of all degrees of freedom
including the CVs, which are not explicitly included in the metadynamics simula-
tion. Therefore, large hysteresis, which is very commonly encountered in standard
metadynamics when important CVs are neglected, can be avoided [287]. We plan
to use this combined scheme to explore the free energy landscape of the cisplatin-
DNA-HMGB1 complex.
Here, we have performed a variety of calculations to derive force field parameters for
the platinated moiety of DNA. We have considered the functional form of AMBER
force field [173] in the parameterization procedure and we will use this for all the
subsequent calculations. The AMBER force field is one of the most widely used force
field for simulations of nucleic acids [289, 290]. Our calculations include a hybrid
Car-Parrinello/molecular mechanics (QM/MM) simulation [167, 168, 169, 170, 171],
force matching procedure [174, 175] and a 200-ns-long classical MD simulation.
In the next sections, we will present results from these calculations
5.2 Derivation of force field parameters for the plati-
nated moiety
5.2.1 QM/MM simulation
The QM/MM simulation was based on the X-ray structure of cisplatin-d(CCUCTCT-
G*G*ACCTTCC) -d(GGAGAGACCTGGAAGG) in complex wih HMGB1 domain
A (PDB code 1CKT) (Fig. 5.2) [76]. The complex were immersed in a box of water,
Na+ ions were added to neutralize the total charge (See Tab. 5.1 for details of the
simulation setup). The whole system underwent 5ns-long preliminary classical MD
simulation, in which the cisplatin moiety was kept fixed with SHAKE algorithm
[235]. The Amber99SB-ILDN force field [173, 190, 191] was used for the protein and
DNA. TIP3P model was used for waters [192] whereas Joung&Cheatham force field
[194] was used for ions. The NAMD program [186] was used to carry out the MD
simulation. The last snapshot was selected for the subsequent QM/MM simulation.
The CPMD program [188] combined with the classical MD Gromos96 code [189],
through the interface developed by Rothlisberger et al. [168, 169] was used for the
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Table 5.1 Selected features of the qmmm simulation box.
Table 5.2 Comparison of the selected structural features of QM/MM, classical MD
models with those of the X-ray structure. See Fig. 5.5 for the atom type
convention.
QM/MM simulation. The QM part includes two guanine bases G8 and G9, the
Pt2+ metal and two ammine (NH3) group. The MM part consist of the rest of the
simulation box (see Tab. 5.1 for more details). The QM/MM procedure is the same
as that of the platinated Mets7 in chapter 4.
Figure 5.3 shows the backbone RMSD of the QM/MM trajectory. There is no signif-
icant structural change during the 20-ps-long QM/MM simulation (RMSD between
the first and the last snapshot ∼ 1.0 A˚). The structural parameters of DNA such as
helix bend, torsional angles were calculated by using the Web server Curves+ [292].
Table 5.2 shows comparison of the selected structural features of Pt-coordination and
DNA between QM/MM and X-ray structures. The results obtained from QM/MM
simulation do not differ significantly from the X-ray structure.
5.2.2 Force matching procedure
Next, the force matching technique of Refs. [174, 175] was applied to 200 conforma-
tions selected from the QM/MM trajectory to obtain the AMBER-type [173] force
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HMGB1 
DNA 
platinated 
guanines 
Figure 5.2 Complex of platinated DNA-HMGB1. The backbone conformations
of X-ray structure (red), the QM/MM structure (blue) and the classi-
cal MD structure (green) are superimposed. Platinated guanines are
shown in ball-and-stick.
field parameters for the plaitaned moiety. The procedure is essentially the same as
that used for the platinated Mets7 in chapter 4.
Partial charges are reported in Tab. 5.3. To minimize changes in original AM-
BER bonded parameters, only bonded parameters involved cisplatin moiety were
parameterized. These parameters are reported in Tabs. 5.4–5.5.
5.3 Force field based MD simulation
The newly derived parameters together with the Amber99SB-ILDN force field [173,
190, 191] and the Barcelona modification [291] has be used to carry out a 200ns-long
classical MD simulation for the cisplatin-DNA-HMGB1 complex. The backbone
RMSD is reported in Fig. 5.6 and some structural features in Tab. 5.2. The classi-
cal model reproduces well the Pt coordination geometry of the QM/MM simulation.
Furthermore, during this 200ns-long classical MD simulation, the system is very
stable (Fig. 5.6) and does not deviate significantly from the X-ray structure (the
averaged RMSD with respect to the X-ray structure is ∼ 3A˚). Most of the impor-
tant contacts between the platinated DNA and HMGB1 in the X-ray structure are
preserved during the classical MD simulation (Fig. 5.7–5.8).
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Figure 5.3 The backbone RMSD of QM/MM trajectory.
5.4 Summary
In summary, the AMBER-type force field parameters for the platinated site in the
cisplatin-DNA-HMGB1 complex has been derived using the force matching proce-
dure [174, 175] for the QM/MM trajectory. Then the system has been equilibrated
for 200ns with classical MD simulation based on the newly derived force field param-
eters for the platinated moiety and the Amber99SB-ILDN force field [173, 190, 191]
with the Barcelona modification [291] for the rest of the complex. This equilibrated
structure will be used for the subsequent metadynamics simulations.
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Table 5.3 Partial charges (in fraction of electronic charge) derived from the force
matching procedure for the cisplatin-DNA-HMGB1 complex. See Fig.
5.4 for the atom name convention.
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Table 5.4 The harmonic force constant Kr (kcal/mol A˚
−2), Kθ (kcal/mol rad−2)
of bond stretching and angle bending, respectively, derived from the
force matching procedure for the cisplatin-DNA-HMGB1 complex. req
(A˚) and θeq (degree) are equilibrium bond lengths and bond angles,
respectively. See Fig. 5.5 for the atom type convention.
Table 5.5 Force constant of dihedral angles (kcal/mol) obtained from the force
matching procedure. See Fig. 5.5 for the atom type convention.
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Figure 5.4 Atom name convention used for parameterization of partial charges.
N6 N7 
Pt 
H7 
H6 
N5 N4 
CK 
H5 
CB 
C 
CB 
CK 
H5 
CB 
C 
CB 
G9 G8 
Figure 5.5 Atom type convention used for parameterization of bonded parameters.
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Figure 5.6 The backbone RMSD of classical MD trajectory.
 0
 2
 4
 6
 8
 10
 12
 0  50  100  150  200
No
. H
-b
on
ds
time (ns)
Figure 5.7 Number of hydrogen bonds between the platinated DNA and HMGB1
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Figure 5.8 The contact map, which is defined as matrix of the smallest distances
between pairs of residues, of the X-ray structure (a) and the classical
MD trajectory (b).
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6
Summary and outlooks
Cisplatin is one of the most potent drugs against testicular, ovarian, cervical, head
and neck, esophageal, and small-cell lung cancers [1, 2, 4, 8]. Its beneficial effect
arises from its binding to DNA [1, 2, 3, 4, 9]. Unfortunately, cisplatin suffers from
several drawbacks, including drug resistance, which severely limits its efficacy, since
only a small fraction of the drug reaches the target DNA [87, 30]. In addition,
cisplatin-DNA adducts can be removed by Nucleotide Excision Repair (NER) pro-
teins [2, 28, 86, 98]. Understanding and eventually overcoming these severe problems
require a detailed knowledge of how cisplatin interacts with a variety of proteins in
the cell. Whilst experiments are providing a great amount of knowledge on the molec-
ular basis of resistance, computational biophysical studies on cisplatin resistance are
basically lacking. This thesis has contributed to two aspects of cisplatin/protein
interactions, which are relevant to the toxicity and the limited uptake of the drug,
using computational physics tools.
(i) We have studied the binding of cisplatin and its isomer transplatin to a model
peptide (named Mets7), that mimics one of the metal binding motifs found at
the extracellular domain of Ctr1. Mets7 has been shown to be an excellent
model for investigating interactions of platinum drugs with Ctr1 in vitro and
in-cell conditions. In order to characterize the structural and spectroscopic
properties of the adducts of cisplatin/transplatin with Mets7, we have used
an arsenal of computational tools, based on hybrid Car-Parrinello/molecular
mechanics (QM/MM) simulations, force matching technique, replica exchange
MD simulations and computational spectroscopy approaches. Our calculated
spectroscopic properties such as NMR, EXAFS and CD have been compared
with the corresponding experimental data to validate our predictions. This
allows us to elucidate the different reaction modes of cisplatin and transplatin
towards Ctr1 and to propose the most relevant species. The molecular mod-
els arising from our calculations can serve as the molecular basis for further
attempts to understand mechanism of cisplatin uptake mediated by Ctr1.
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Other copper transport proteins such as the copper chaperone Atox1 and cop-
per pumps ATP7A/ATP7B have been found to bind cisplatin in vitro and in
vivo. However, the structural information of these cisplatin-protein adducts is
mostly lacking. Therefore, the computational strategies which have been em-
ployed here for structural prediction cisplatin/transplatin-Mets7 adducts can
be extended to these systems. Recently, a project focusing on the adducts of
Atox1 and ATP7B with cisplatin, based on the same computational protocol
for Ctr1, has been approved by Deutsche Forschungsgemeinschaft (DFG).
(ii) We have carried out preliminary calculations of platinated DNA binding to
the HMGB1 protein. Resistance to cisplatin is also linked to the ability of the
resistant cells to repair DNA damages induced by cisplatin via the NER repair
pathway. Fortunately, HMGB1 protein may be able to prevent NER by binding
to the cisplatin-DNA adduct and shielding it from being repaired by NER
enzymes. Understanding the binding mechanism of platinated DNA to HMGB1
protein is, therefore, a fundamental step towards understanding molecular basis
of cisplatin resistance mechanisms. Here we address this issue by investigating
structural and energetic properties of cisplatin-DNA adduct binding to HMGB1
protein using free energy calculations based on metadynamics. In this thesis,
we have performed a QM/MM simulation and force matching procedure to
parameterize the force field for the platinated moiety. Then the system has
been equilibrated in aqueous solution for 200ns. These preliminary calculations
are used to prepare the system for the more expensive free energy calculations.
From the preliminary results obtained in (ii) we plan to combine well-tempered
metadynamics with parallel tempering to calculate the free energy profile of the
binding of cisplatin-DNA adduct to HMGB1 protein. The combined scheme
provides an efficient way to explore very complex free energy landscapes and
allows large free energy barrier to be easily overcome. Therefore, it allows
studies of very complex processes such as molecular recognition, which requires
extensive sampling of the association/disassociation processes. However, this
approach is very computationally demanding. Therefore, we have requested
computing resource from PRACE [293] and our proposal is under evaluation.
A
Appendix
A.1 DFT-based geometry optimization of the model
compounds
The model compounds are [Pt(SH2)3Cl]
+, [Pt(SH2)3H2O]
2+, [Pt(SH2)3OH]
+ and
trans-[Pt(SH2)2(NH3)2]
2+ (Fig. A.1) which were energy-minimized at the DFT level
using the CPMD program [188]. Exchange and correlation functional were those
of Becke [195] and of Lee, Yang and Parr [196] (BLYP), respectively. Kohn-Sham
orbitals were expanded in plane waves up to 70 Ry. The core electrons were described
using norm-conserving pseudopotentials of the Martins-Troullier type [197]. Isolated
system conditions have been applied [198]. GDIIS method [234] was used to optimize
the structures of the model compounds with a convergence criterion of 10−6 for the
largest component of the energy gradient. The results of structural parameters are
reported in Tab. A.1.
A.2 Conversion of NMR chemical shifts
For 1H, the NMR chemical shift was calculated as:
δH(X) = σH(TMS)− σH(X), (A.1)
where σH(TMS) is the 1H shielding constant calculated for an isolated TMS molecule
using the same DFT level [210]. Vibration and rotation can contribute significantly
to the calculated 13C NMR shielding constant of TMS [210]. It is, therefore, im-
portant to use the shielding constant of a simpler molecule (such as CH4 or C2H6)
as a computational reference. In this case, the chemical shielding constants were
referenced indirectly to TMS via the calculated 13C shielding constant and the ex-
perimental chemical shift of C2H6 [210]. Namely, this is achieved via the identity:
δC(X) = σC(TMS)− σC(X) = δCexp (C2H6) +
[
σC(C2H6)− σC(X)
]
calc
. (A.2)
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The value for δCexp(C2H6) was taken from ref. [238]. Due to the use of pseudopoten-
tials to describe the interactions between valence and core electrons, the calculated
13C chemical shielding constants do not account for the effect of the core electrons
[239]. Such a constant is effectively canceled out by the equation A.2.
A.3 QM/MM simulations and 195Pt NMR chemical
shielding calculation of the reference compound
[PtCl6]2−
The molecule [PtCl6]
2− was built as a new AMBER residue using Antechamber
package [240]. The Gaussian 09 program [241] was used to optimize the structure
of [PtCl6]
2− and to calculate the RESP charges [242]. The system was inserted in
a box of 1000 water molecules. 2 Na+ ions were added to neutralize the system.
The 5 ns-long classical MD simulation was performed with the same setup as that of
the preliminary simulations of the platinated peptides (see Sec. 4.2.1). During the
MD simulation, the structure of [PtCl6]
2− was kept fixed. Then 10ps-long QM/MM
simulation was carried out based on the last MD snapshot. QM part is the molecule
and the MM part is the solvent and counterions. The QM/MM simulation procedure
was the same as that of the platinated peptides (see Sec. 4.2.2). 50 equidistant snap-
shots were extracted from the QM/MM simulation for the 195Pt chemical shielding
calculation. The 195Pt chemical shielding calculation procedure was the same as that
for the platinated peptides (See Sec. 4.2.5.2).
A.4 Sampling of the QM region by QM/MM simula-
tions
As shown in (Fig. A.3), the RMSD of the QM parts show that the local geometry
around the platinum ion is stable during the QM/MM simulations. The RMSD
of the T1 model shows a small increase near the end (at ∼20 ps) of the 25 ps-
long trajectory (Fig. A.3). We compared the structures at the beginning of the
simulation, after few ps and at the end of the simulation. The increase in RMSD is
basically due to the change in the orientation of the two ammine groups. Indeed, the
two ammine groups rotate around the S(Met1)-S(Met4) axis by approximately 15◦.
The rest of the T1 model essentially fluctuates around an average position. This
movement does not affect the calculated values of NMR shifts reported in Tab. A.9
and A.11.
The sampling of the QM region was further checked by performing the principal
component analysis and calculating the cosine contents of the first few principal
components [224]. The cosine contents for all six systems are small and do not show
any sign of poor sampling (Tab. A.7). It should be noted that the cosine content
used here is a good indicator for bad sampling. If the cosine content has a large
value (close to 1), then the sampling is surely not sufficient. However, the reverse
is not necessarily true. A small value of the cosine content is a necessary but not
sufficient condition for a good sampling.
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A.5 Metadynamics method
The free energy as a function of d collective variables (Cvs)
S
({
~RI
})
=
{
S1
({
~RI
})
, . . . , Sd
({
~RI
})}
(A.3)
is given by [284, 285]
F (S) = −kBT ln
∫
d~Rd~P exp
−H
(
~R, ~P
)
kBT
 δ (S − S (~R)). (A.4)
The CVs should be chosen so as to distinguish between the initial and final state,
describe all the relevant intermediates and include the slow modes, which cannot
be satisfactorily sampled in the time scale of a standard MD simulation. There
are several methods for evaluating F (S). Among these, metadynamics adds an
external history-dependent bias potential function of the CVs S and time t to the
Hamiltonian:
HMetaD = H
(
~R, ~P
)
+ V (S, t) . (A.5)
V (S, t) is written as a sum of Gaussians of widths σi(i = 1, . . . , d) and height ω
deposited along the system trajectory in the S
({
~RI
})
space to discourage the
system from revisiting configurations that have already been sampled. V (S, t) may
be applied continuously during a MD simulation on the coordinates of the system:
V (S, t) = ω
t∫
0
dt′ exp
−12
d∑
i=1
Si
(
{~RI}
)
− Si
(
{~RI(t′)}
)
σi
2
. (A.6)
Hence, metadynamics pushes the system away from local free energy minima, al-
lowing it to explore reaction pathways since the system tends to escape the minima
passing through the lowest free-energy saddle point.
Eventually, V (S, t) provides the underlying free energy:
F (S) = −V (S, t→∞) + C, (A.7)
where C is an irrelevant additive constant. Hence, metadynamics does not require
a priori knowledge of the landscape. However, −V (S, t) does not converge modulo
a constant to the free energy, but oscillates around it. Hence, it is not trivial to
decide when to stop a simulation. A solution to this problem has been provided by
the well-tempered metadynamics [286]. Here the bias deposition rate decreases over
simulation time, thus the dynamics becomes closer and closer to thermodynamic
equilibrium as the simulation proceeds. The bias potential is given by
V (S, t) = kB∆T ln
(
1 +
W
τ
N(S, t)
kB∆T
)
, (A.8)
where N(S, t) is the histogram of the S variables collected during the simulation,
∆T and W are two input parameters with the dimension of a temperature and an
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energy, respectively, and τ is he time interval between two consecutive Gaussian
depositions. Here, the bias potential converges in a single run. The probability
distribution of the CVs can be shown to be proportional to:
P (S, t→∞) ∝ exp
[
− F (S)
kB (T + ∆T )
]
. (A.9)
For ∆T → 0 and ∆T → ∞ we have standard MD and standard metadynamics,
respectively. The free energy in well-tempered metadynamics can be shown to con-
verge to:
F (S) = −T + ∆T
∆T
V (S, t→∞) + C. (A.10)
To decrease the effect of neglecting slow degrees of freedom in the choice of the CVs,
one can use a combination of metadynamics with parallel tempering (PT). In this
combined scheme, M copies (replicas) of the same system undergo metadynamics at
different temperatures T1 < T2 < . . . < TM . The exchange of configurations between
two adjacent replicas (at Ti and Ti+1) is attempted with the probability
p (i→ i+ 1) = min {1,∆i,i+1} ; i = 2, . . . ,M, (A.11)
where
∆i,i+1 = exp
[(
1
kBTi
− 1
kBTi+1
)(
U
({
~RI
}i)
− U
({
~RI
}i+1))
+
V i
(
S
({
~RI
}i))
− V i
(
S
({
~RI
}i+1))
kBTi
+
V i+1
(
S
({
~RI
}i))
− V i+1
(
S
({
~RI
}i+1))
kBTi+1
 (A.12)
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A.6 Supporting tables and figures
[Pt(SH2)3Cl]+! [Pt(SH2)3H2O]2+!
[Pt(SH2)3OH]+! trans[Pt(SH2)2(NH3)2]2+!
Figure A.1 DFT optimized model compounds
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Table A.1 Structural parameters of the model compounds optimized at the DFT
level in gas phase. Scis and Strans are sulphur atoms cis and trans to
the fourth ligand (chloride, water molecule, or OH− group).
Table A.2 Charges (in fraction of electronic charge) derived from the force match-
ing procedure for the cisplatin-Mets7 adduct models. See Fig. A.2 for
the atom name convention.
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Table A.3 Charges (in fraction of electronic charge) derived from the force match-
ing procedure for the transplatin-Mets7 adduct models. See Fig. A.2
for the atom name convention.
Table A.4 The harmonic force constant Kr of bond stretching (kcal/mol A˚
−2)
and equilibrium bond lengths req (A˚) obtained from the force matching
procedure. See Fig. A.2 for the atom type convention.
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Table A.5 The harmonic force constant of angle bending (kcal/mol rad−2) and
equilibrium bond angles (degree) obtained from the force matching pro-
cedure. See Fig. A.2 for the atom type convention.
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Table A.6 Force constant of dihedral angles (kcal/mol) obtained from the force
matching procedure. See Fig. A.2 for the atom type convention.
Table A.7 The cosine content of the first four principal components of the QM
region in the QM/MM simulations.
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Table A.8 NMR chemical shifts of C1-C3 (13C (top) and 1H (bottom)) obtained
from QM/MM simulations before REST simulations.
Table A.9 NMR chemical shifts of T1-T3 (13C (top) and 1H (bottom)) obtained
from QM/MM simulations before REST simulations.
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Table A.10 NMR chemical shifts of Apo (13C (top) and 1H (bottom)) obtained
from QM/MM simulations for the representative snapshot of the
REST trajectory. The RMSD of this representative snapshot relative
to the last REST one is 3.3 A˚.
Table A.11 195Pt NMR chemical shifts obtained from QM/MM simulations before
REST simulations.
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Figure A.2 Atom name and atom type convention for the QM atoms. The atom
names are in bold and atom types in italics. Hydrogen atoms are not
shown for the sake of clarity
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Figure A.3 RMSD of the QM region during the Car-Parrinello QM/MM simula-
tions. Left: cisplatin-Mets7, right: transplatin-Mets7.
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